Document:

EX-4.4

 Exhibit 4.4 

EXECUTION VERSION 

DECIPHER BIOSCIENCES, INC. 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of May 15,
2020 (the “Effective Date”), by and among DECIPHER BIOSCIENCES, INC., a Delaware corporation (the “Company”), and each of the investors listed on Schedule
A attached hereto (each, an “Investor,” and collectively, the “Investors”). 
 RECITALS

 WHEREAS, the Company and certain Investors are parties to that certain Amended and Restated Investors’ Rights Agreement,
dated March 29, 2019 (the “Prior Agreement”); 
 WHEREAS, certain of the Investors (the “Series 4
Investors”) have agreed to purchase from the Company, and the Company has agreed to sell to the Series 4 Investors, shares of Series 4 Preferred (as defined below) on the terms and conditions set forth in the Series 4 Preferred Stock and
Note Purchase Agreement dated of even date herewith, by and among the Company and the Series 4 Investors (the “Purchase Agreement”); 

WHEREAS, the obligations in the Purchase Agreement are conditioned upon the execution and delivery of this Agreement; 

WHEREAS, Section 6.7 of the Prior Agreement provides that the Prior Agreement may be amended only with the
written consent of the Company and the holders of at least a majority of the Registrable Securities (as defined in the Prior Agreement) outstanding immediately prior to the execution of this Agreement; and 

WHEREAS, the parties to the Prior Agreement desire to amend and restate the Prior Agreement and accept the rights and covenants hereof
in lieu of their rights and covenants under the Prior Agreement. 
 NOW, THEREFORE, the parties hereby agree as follows: 

1. Definitions. For purposes of this Agreement: 

1.1 “Affiliate” and its correlative terms mean, with respect to any specified Person, any other Person who, directly or
indirectly, controls, is controlled by, or is under common control with such Person, including, without limitation, any general partner, managing member, investment adviser, officer, trustee or director of such Person or any venture capital fund or
registered investment company now or hereafter existing that is controlled by one or more general partners or managing members of, or shares the same management company or investment adviser with, such Person. 

1.2 “Certificate of Incorporation” means the Company’s Amended and Restated Certificate of Incorporation, as amended
from time to time. 
 1.3 “Common Stock” means the Company’s Common Stock, par value $0.0001 per share. 

  
 1. 

 1.4 “Damages” means any loss, damage, or liability (joint or several) to
which a party hereto may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, or liability (or any action in respect thereof) arises out of or is based upon (i) any untrue
statement or alleged untrue statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto; (ii) an
omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by the indemnifying party (or any of its
agents or Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law. 

1.5 “Derivative Securities” means any securities or rights convertible into, or exercisable or exchangeable for (in each
case, directly or indirectly), Common Stock, including options and warrants. 
 1.6 “Exchange Act” means the Securities
Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. 
 1.7 “Excluded Registration”
means (i) a registration relating to the sale of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, employee benefit or similar plan; (ii) a registration relating to a corporate
reorganization or other SEC Rule 145 transaction; (iii) a registration on any registration form that does not permit secondary sales; (iv) a registration on any form that does not include substantially the same information as would be
required to be included in a registration statement covering the sale of the Registrable Securities; or (v) a registration relating to the offer and sale of debt securities and/or Common Stock issuable upon conversion of those debt securities.

 1.8 “Exempted Securities” has the meaning given to such term in the Certificate of Incorporation. 

1.9 “Form S-1” means such form under the Securities Act as in effect on the date
hereof or any successor registration form under the Securities Act subsequently adopted by the SEC. 
 1.10 “Form S-3” means such form under the Securities Act as in effect on the date hereof or any successor or similar registration form under the Securities Act subsequently adopted by the SEC that permits
incorporation of substantial information by reference to other documents filed by the Company with the SEC. 
 1.11 “GAAP”
means generally accepted accounting principles in the United States. 
 1.12 “Holder” means any holder of Registrable
Securities who is a party to this Agreement. 
 1.13 “Immediate Family Member” means a child, stepchild, grandchild,
parent, stepparent, grandparent, spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-

  
 2. 

 
law, brother-in-law, or
sister-in-law, including adoptive relationships, of a natural person referred to herein. 

1.14 “Initiating Holders” means, collectively, Holders who properly initiate a registration request under this Agreement.

 1.15 “IPO” means the Company’s first underwritten public offering of its Common Stock under the Securities Act.

 1.16 “Key Employee” means any executive-level employee (including division director and vice president-level positions)
as well as any employee who, either alone or in concert with others, develops, invents, programs, or designs any Company Intellectual Property (as defined in the Purchase Agreement). 

1.17 “Major Investor” means any Investor that, individually or together with such Investor’s Affiliates, holds at least
2,200,000 shares of Preferred Stock (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after the date hereof). 

1.18 “Majority Preferred Directors” means the affirmative vote or written consent by at least a majority of the Preferred
Directors. 
 1.19 “New Securities” means, collectively, equity securities of the Company, whether or not currently
authorized, as well as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity securities. 

1.20 “Novalis” means Novalis LifeSciences Investments I, L.P. and its Affiliates. 

1.21 “Person” means any individual, corporation, partnership, trust, limited liability company, association or other entity.

 1.22 “Preferred Directors” has the meaning given to it in the Voting Agreement. 

1.23 “Preferred Stock” means, collectively, the Company’s Series 1 Preferred Stock, the Company’s Series 2
Preferred Stock, the Company’s Series 3 Preferred Stock (“Series 3 Preferred”) and the Company’s Series 4 Preferred Stock (“Series 4 Preferred”). 

1.24 “Preferred Stockholders” means the holders of Preferred Stock and “Preferred Stockholder” means any one
of them. 
 1.25 “Qualified Initial Public Offering” has the meaning set forth in the Certificate of Incorporation. 

1.26 “Registrable Securities” means (i) the Common Stock issuable or issued upon conversion of the Preferred Stock;
(ii) any Common Stock, or any Common Stock issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities of the 

  
 3. 

 
Company, acquired by the Investors after the date hereof; and (iii) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is
issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in clauses (i) and (ii) above; excluding in all cases, however, any Registrable Securities sold by a Person in a
transaction in which the applicable rights under this Agreement are not assigned pursuant to Section 6.1, and excluding for purposes of Section 2 any shares for which registration rights have terminated pursuant to
Section 2.13 of this Agreement. Notwithstanding the foregoing, the Company shall in no event be obligated to register any Preferred Stock, and Holders of Registrable Securities will not be required to convert their
Preferred Stock into Common Stock in order to exercise the registration rights granted hereunder, until immediately before the closing of the offering to which the registration relates. 

1.27 “Registrable Securities then outstanding” means the number of shares determined by adding the number of shares of
outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant to then exercisable and/or convertible securities that are Registrable Securities. 

1.28 “Restricted Securities” means the securities of the Company required to bear the legend set forth in
Section 2.12(b). 
 1.29 “SEC” means the United States Securities and Exchange Commission. 

1.30 “SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act. 

1.31 “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act. 

1.32 “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 1.33 “Selling Expenses” means all underwriting discounts, selling commissions, and stock transfer taxes applicable to
the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as provided in Section 2.6. 

1.34 “Tekla Funds” means, collectively, Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla World Healthcare
Fund, Tekla Healthcare Opportunities Fund and/or any Affiliates of the foregoing. 
 1.35 “Voting Agreement” means that
certain Amended and Restated Voting Agreement, by and among the Company, the Investors and certain stockholders of the Company of even date herewith. 

2. Registration Rights. The Company covenants and agrees as follows: 

  
 4. 

 2.1 Demand Registration. 

(a) Form S-1 Demand. If (i) at any time after five (5) years after
July 20, 2018, the Company receives a request from Holders of a majority of the Registrable Securities then outstanding, that the Company file a Form S-1 registration statement with respect to Registrable
Securities then outstanding having an anticipated aggregate offering price of at least $20,000,000 or, if earlier, (ii) at any time after one hundred eighty (180) days after the effective date of the registration statement for the IPO, the
Company receives a request from Holders of at least thirty percent (30%) of the Registrable Securities then outstanding, that the Company file a Form S-1 registration statement with respect to Registrable
Securities then outstanding having an anticipated aggregate offering price of at least $10,000,000, then, in each case, the Company shall (a) within ten (10) days after the date such request is given, give notice thereof (the
“Demand Notice”) to all Holders other than the Initiating Holders; and (b) as soon as practicable, and in any event within sixty (60) days after the date such request is made by the Initiating Holders, file a Form S-1 registration statement under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in
such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days after the date the Demand Notice is given, and in each case, subject to the limitations of
Section 2.1(c) and Section 2.3. 
 (b) Form
S-3 Demand. If at any time when it is eligible to use a Form S-3 registration statement, the Company receives a request from Holders of at least twenty-five
percent (25%) of the Registerable Securities then outstanding that the Company file a Form S-3 registration statement with respect to Registrable Securities then outstanding, of such Holders having an
anticipated aggregate offering price, net of selling expenses, of at least $3,000,000, then the Company shall (i) within ten (10) days after the date such request is given, give a Demand Notice to all Holders other than the Initiating
Holders; and (ii) as soon as practicable, and in any event within forty-five (45) days after the date such request is made by the Initiating Holders, file a Form S-3 registration statement under the
Securities Act covering all Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days after the date the Demand Notice is
given, and in each case, subject to the limitations of Section 2.1(c) and Section 2.3. 

(c) Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant to this
Section 2.1 a certificate signed by the Company’s Chief Executive Officer or other most senior executive officer stating that in the good faith judgment of the Company’s Board of Directors (the “Board of
Directors”) it would be materially detrimental to the Company and its stockholders for such registration statement to be filed in the near future and that it is, therefore, in the best interests of the Company to defer the filing of such
registration statement, then the Company shall have the right to defer taking action with respect to such filing, and any time periods with respect to filing or effectiveness thereof shall be tolled correspondingly, for a period of not more than
ninety (90) days after the request of the Initiating Holders is given; provided, however, that the Company may not invoke this right more than once in any twelve (12) month period; and provided further, that the Company
shall not register any securities for its own account or that of any other stockholders during such ninety (90) day period other than an Excluded Registration. 

  
 5. 

 (d) The Company shall not be obligated to effect, or to take any action to effect, any
registration pursuant to Section 2.1(a): (i) during the period that is within ninety (90) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is one hundred eighty (180) days
after the effective date of, a Company-initiated registration; provided, that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; (ii) after the
Company has effected two registrations pursuant to Section 2.1(a); or (iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Section 2.1(b). The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Section 2.1(b) (i)
during the period that is within thirty (30) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is ninety (90) days after the effective date of, a Company-initiated registration;
provided, that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; or (ii) if the Company has effected one registration at the request of Holders of
Registrable Securities pursuant to Section 2.1(b) within the twelve (12) month period immediately preceding the date of such request. A registration shall not be counted as “effected” for purposes of this
Section 2.1(d) until such time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw their request for such registration, elect not to pay the registration
expenses therefor, and forfeit their right to one demand registration statement pursuant to Section 2.6, in which case such withdrawn registration statement shall be counted as “effected” for purposes of this
Section 2.1(d). 
 2.2 Company Registration. If the Company proposes to register (including, for this
purpose, a registration effected by the Company for stockholders other than the Holders) any Common Stock under the Securities Act in connection with the public offering of such securities solely for cash (other than in an Excluded Registration),
the Company shall, at such time, promptly give each Holder notice of such registration. Upon the request of each Holder given within twenty (20) days after such notice is given by the Company, the Company shall, subject to the provisions of
Section 2.3, use its commercially reasonable efforts to include in such registration all of the Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the
right to terminate or withdraw any registration initiated by it under this Section 2.2 before the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such
registration. The expenses (other than Selling Expenses) of such withdrawn registration shall be borne by the Company in accordance with Section 2.6. 

2.3 Underwriting Requirements. 

(a) If, pursuant to Section 2.1, the Initiating Holders intend to distribute the Registrable Securities
covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Section 2.1, and the Company shall include such information in the Demand Notice. The
underwriter(s) will be selected by the Company and shall be reasonably acceptable to at least a fifty-five percent (55%) in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder’s Registrable
Securities in such registration shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing
to distribute their securities through such underwriting shall (together with the Company as provided in Section 2.4(e)) enter into an 

  
 6. 

 
underwriting agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding any other provision of this Section 2.3, if the managing
underwriter(s) advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities that otherwise would
be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among such Holders of Registrable Securities, including the Initiating Holders, in proportion (as nearly as
practicable) to the number of Registrable Securities owned by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders; provided, however, that the number of Registrable Securities held by the Holders
to be included in such underwriting shall not be reduced unless all other securities of the Company are first entirely excluded from the underwriting. To facilitate the allocation of shares in accordance with the above provisions, the Company or the
underwriters may round the number of shares allocated to any Holder to the nearest one hundred (100) shares. 
 (b) In connection with
any offering involving an underwriting of shares of the Company’s capital stock pursuant to Section 2.2, the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting
unless the Holders accept the terms of the underwriting as agreed upon between the Company and its underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by
the Company. If the total number of securities, including Registrable Securities, requested by stockholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their
reasonable discretion determine is compatible with the success of the offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the
Company in their sole discretion determine will not jeopardize the success of the offering. If the underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the
Registrable Securities that are included in such offering shall be allocated among the selling Holders in proportion (as nearly as practicable to) to the number of Registrable Securities (regardless of class) owned by each selling Holder or in such
other proportions as shall mutually be agreed to by all such selling Holders. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to
the nearest one hundred (100) shares. Notwithstanding the foregoing, in no event shall (i) the number of Registrable Securities included in the offering be reduced unless all other securities (other than securities to be sold by the
Company) are first entirely excluded from the offering or (ii) the number of Registrable Securities included in the offering be reduced below thirty percent (30%) of the total number of securities included in such offering, unless such offering
is the IPO, in which case the selling Holders may be excluded further if the underwriters make the determination described above and no other stockholder’s securities are included in such offering. For purposes of the provision in this
Section 2.3(b) concerning apportionment, for any selling Holder that is a partnership, limited liability company, corporation or other entity, the partners, members, retired partners, retired members, stockholders, and
Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts for the benefit of any of the foregoing Persons, shall be deemed to be a single “selling
Holder,” and any pro rata reduction with respect to such “selling Holder” shall be based upon the aggregate number of Registrable Securities owned by all Persons included in such “selling Holder,” as defined in this
sentence. 

  
 7. 

 (c) For purposes of Section 2.1, a registration shall not be
counted as “effected” if, as a result of an exercise of the underwriter’s cutback provisions in Section 2.3(a), fewer than fifty percent (50%) of the total number of Registrable Securities that
Holders have requested to be included in such registration statement are actually included. 
 2.4 Obligations of the Company.
Whenever required under this Section 2 to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 

(a) prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable
efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period of up to one hundred
twenty (120) days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that (i) such one hundred twenty (120) day period shall be extended for a period of time
equal to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration, and (ii) in the case of any registration of Registrable
Securities on Form S-3 that are intended to be offered on a continuous or delayed basis, subject to compliance with applicable SEC rules, such one hundred twenty (120) day period shall be extended for up
to sixty (60) days, if necessary, to keep the registration statement effective until all such Registrable Securities are sold; 
 (b)
prepare and file with the SEC such amendments and supplements to such registration statement, and the prospectus used in connection with such registration statement, as may be necessary to comply with the Securities Act in order to enable the
disposition of all securities covered by such registration statement for the period set forth in Section 2.4(a); 

(c) furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the Securities
Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

(d) use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other
securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided, however, that the Company shall not be required to qualify to do business or to file
a general consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(e) in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and
customary form, with the underwriter(s) of such offering, provided such underwriting agreement contains reasonable and customary provisions, and provided further, that each Holder participating in such underwriting shall also enter
into and perform its obligations under such an agreement; 

  
 8. 

 (f) use its commercially reasonable efforts to cause all such Registrable Securities
covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed; 

(g) provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number
for all such Registrable Securities, in each case not later than the effective date of such registration; 
 (h) promptly make available
for inspection by the selling Holders, any managing underwriter(s) participating in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling
Holders, all financial and other records, pertinent corporate documents, and properties of the Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any
such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; 

(i) notify each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been
declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and 
 (j) after such
registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or supplement such registration statement or prospectus. 

2.5 Furnish Information. It shall be a condition precedent to the obligations of the Company to take any action pursuant to this
Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and the intended method of
disposition of such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities. 
 2.6
Expenses of Registration. All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or qualifications pursuant to Section 2, including all registration, filing, and qualification
fees; printers’ and accounting fees; fees and disbursements of counsel for the Company; and the reasonable fees and disbursements, not to exceed $50,000, of one counsel for the selling Holders (“Selling Holder Counsel”),
shall be borne and paid by the Company; provided, however, that the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to Section 2.1 if the registration request is
subsequently withdrawn at the request of the Holders of seventy percent (70%) of the Registrable Securities to be registered (in which case all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities
that were to be included in the withdrawn registration), unless the Holders of seventy percent (70%) of the Registrable Securities agree to forfeit their right to one registration pursuant to Section 2.1(a) or
Section 2.1(b); provided further, that if, at the time of such withdrawal, the Holders shall have learned of a material adverse change in the condition, 

  
 9. 

 
business, or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness after learning of such information then
the Holders shall not be required to pay any of such expenses and shall not forfeit their right to one registration pursuant to Section 2.1(a) or Section 2.1(b). All Selling Expenses relating to Registrable Securities
registered pursuant to this Section 2 shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities registered on their behalf. 

2.7 Delay of Registration. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any
registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 

2.8 Indemnification. If any Registrable Securities are included in a registration statement under this
Section 2: 
 (a) To the extent permitted by law, the Company will indemnify and hold harmless each selling
Holder, and the partners, members, officers, directors, trustees, investment advisors and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities Act) for each such Holder;
and each Person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other
aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided that the indemnity
agreement contained in this Section 2.8(a) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be
unreasonably withheld, nor shall the Company be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such
Holder, underwriter, controlling Person, or other aforementioned Person expressly for use in connection with such registration. 
 (b) To
the extent permitted by law, each selling Holder, severally and not jointly, will indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls
the Company within the meaning of the Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person
of any such underwriter or other Holder, against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on
behalf of such selling Holder expressly for use in connection with such registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection
with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Section 2.8(b) shall not apply
to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; and provided further, that in no

  
 10. 

 
event shall the aggregate amounts payable by any Holder by way of indemnity or contribution under Sections 2.8(b) and 2.8(d) exceed the proceeds from the offering
received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Holder. 

(c) Promptly after receipt by an indemnified party under this Section 2.8 of notice of the commencement of any
action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this
Section 2.8, give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate
jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified
parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel
retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure to give notice to the indemnifying
party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this Section 2.8, to the extent that such failure materially
prejudices the indemnifying party’s ability to defend such action. The failure to give notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this
Section 2.8. 
 (d) To provide for just and equitable contribution to joint liability under the Securities Act in
any case in which either (i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Section 2.8 but it is judicially determined (by the entry of a final judgment or
decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this
Section 2.8 provides for indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this
Section 2.8, then, and in each such case, such parties will contribute to the aggregate losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as
is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to
reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material
fact, or the omission or alleged omission of a material fact, relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct
or prevent such statement or omission; provided, however, that, in any such case, (x) no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by such
Holder pursuant to such registration statement, and (y) no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from

  
 11. 

 
any Person who was not guilty of such fraudulent misrepresentation; and provided further, that in no event shall a Holder’s liability pursuant to this
Section 2.8(d), when combined with the amounts paid or payable by such Holder pursuant to Section 2.8(b), exceed the proceeds from the offering received by such Holder (net of any Selling Expenses
paid by such Holder), except in the case of willful misconduct or fraud by such Holder. 
 (e) Notwithstanding the foregoing, to the extent
that the provisions on indemnification and contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting
agreement shall control. 
 (f) Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten
public offering, the obligations of the Company and Holders under this Section 2.8 shall survive the completion of any offering of Registrable Securities in a registration under this Section 2, and
otherwise shall survive the termination of this Agreement. 
 2.9 Reports Under Exchange Act. With a view to making
available to the Holders the benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the Company shall: 
 (a) make and keep available adequate current public information, as those terms
are understood and defined in SEC Rule 144, at all times after the effective date of the registration statement filed by the Company for the IPO; 

(b) use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Company under
the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and 
 (c)
furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent accurate, a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any
time after ninety (90) days after the effective date of the registration statement filed by the Company for the IPO), the Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or
that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after the Company so qualifies); (ii) a copy of the most recent annual or quarterly report of the Company and
such other reports and documents so filed by the Company; and (iii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without
registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form S-3 (at any time after the Company so qualifies to use such form). 

2.10 Limitations on Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not, without the prior
written consent of the Holders of a majority of the Registrable Securities then outstanding, enter into any agreement with any holder 

  
 12. 

 
or prospective holder of any securities of the Company that would (i) provide to such holder the right to include securities in any registration on other than a subordinate basis after all
Holders have had the opportunity to include in the registration and offering all shares of Registrable Securities that they wish to so include or (ii) allow such holder or prospective holder to initiate a demand for registration of any
securities held by such holder or prospective holder. 
 2.11 “Market
Stand-off” Agreement. Each Holder hereby agrees that it will not, without the prior written consent of the managing underwriter, during the period commencing on the date of the
final prospectus relating to the IPO and ending on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (180) days, which period may be extended upon the request of the managing
underwriter, to the extent required by any FINRA rules, for an additional period of up to fifteen (15) days if the Company issues or proposes to issue an earnings or other public release within fifteen (15) days of the expiration of the 180-day lockup period), (i) lend, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right, or warrant to purchase, or
otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common Stock held immediately before the effective date of the
registration statement for such offering or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such securities, whether any such transaction described
in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise. The foregoing provisions of this Section 2.11 shall not apply to the sale of any shares to an
underwriter pursuant to an underwriting agreement, and shall be applicable to the Holders only if all officers and directors are subject to the same restrictions and the Company uses commercially reasonable efforts to obtain a similar agreement from
all stockholders individually owning more than one percent (1%) of the Company’s outstanding Common Stock (after giving effect to conversion into Common Stock of all outstanding Preferred Stock of the Company). The underwriters in connection
with such registration are intended third-party beneficiaries of this Section 2.11 and shall have the right, power, and authority to enforce the provisions hereof as though they were
a party hereto. Each Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with this Section 2.11 or that are necessary
to give further effect thereto. Any discretionary waiver or termination of the restrictions of any or all of such agreements by the Company or the underwriters shall apply pro rata to all Holders subject to such agreements, based on the number of
shares subject to such agreements, provided that this sentence shall not apply to any discretionary waiver or termination under this Section 2.11 if the aggregate number of released shares does not exceeds one percent (1%) of the total
outstanding voting shares of the Company. 
 2.12 Restrictions on Transfer. 

(a) The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company shall not
recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the
provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities 

  
 13. 

 
held by such Holder to agree to take and hold such securities subject to the provisions and upon the conditions specified in this Agreement. 

(b) Each certificate or instrument representing (i) the Preferred Stock, (ii) the Registrable Securities, and (iii) any other
securities issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization, merger, consolidation, or similar event, shall (unless otherwise permitted by the provisions of
Section 2.12(c)) be stamped or otherwise imprinted with a legend substantially in the following form (in addition to any legends required by applicable securities laws and/or a legend restricting resale of such securities):

  

					
		  	 THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR THE SECURITIES LAWS OF ANY STATE, AND
HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF, AND MAY BE OFFERED, SOLD, ASSIGNED, PLEDGED, TRANSFERRED OR OTHERWISE DISPOSED OF IN THE UNITED STATES ONLY PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 OR PURSUANT TO AN APPLICABLE EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933 AND, IF REQUESTED BY DECIPHER BIOSCIENCES, INC. (THE “COMPANY”), UPON DELIVERY OF AN OPINION
OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY AND ITS COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933.
  

THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER, A COPY OF WHICH
IS ON FILE WITH THE SECRETARY OF THE COMPANY.
	  	

 The Holders consent to the Company making a notation in its records and giving instructions to any transfer agent of the
Restricted Securities in order to implement the restrictions on transfer set forth in this Section 2.12. 
 (c)
The holder of each certificate representing Restricted Securities, by acceptance thereof, agrees to comply in all respects with the provisions of this Section 2. Before any proposed sale, pledge, or transfer of any
Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed transaction, the Holder thereof shall give notice to the Company of such Holder’s intention to effect such sale, pledge, or
transfer. Each such notice shall describe the manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if reasonably requested by the Company, shall be accompanied at such Holder’s expense by either
(i) a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the Company, addressed to the Company, to the effect that the proposed transaction may be effected without registration under the
Securities Act; (ii) a “no action” letter from the SEC to the effect that the proposed sale, pledge, or transfer of such Restricted Securities without registration will not result in a recommendation

  
 14. 

 
by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory to counsel to the Company to the effect that the proposed sale, pledge,
or transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to sell, pledge, or transfer such Restricted Securities in accordance with
the terms of the notice given by the Holder to the Company. The Company will not require such a legal opinion or “no action” letter in any transaction in which such Holder distributes Restricted Securities to an Affiliate of such Holder
for no consideration or transfers such Restricted Securities to an Affiliate(s) in connection with a reallocation of such Restricted Securities among such Affiliates, whether with or without consideration; provided that each transferee agrees
in writing to be subject to the terms of this Section 2.12. Each certificate or instrument evidencing the Restricted Securities transferred as above provided shall bear, except if such transfer is made pursuant to SEC
Rule 144, the appropriate restrictive legend set forth in Section 2.12(b), except that such certificate shall not bear such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend
is not required in order to establish compliance with any provisions of the Securities Act. 
 2.13 Termination of Registration
Rights. The right of any Holder to request registration or inclusion of Registrable Securities in any registration pursuant to Section 2.1 or Section 2.2 shall terminate upon the earliest to
occur of: 
 (a) as to such Holder, upon the sale of all shares held by such Holder pursuant to an effective registration statement under
the Securities Act. 
 (b) as to such Holder, such earlier time after the IPO at which such Holder (i) can sell all shares held by it
in compliance with Rule 144(b)(1)(i) or (ii) holds one percent (1%) or less of the Company’s outstanding Common Stock and all Registrable Securities held by such Holder (together with any Affiliate of the Holder with whom such Holder must
aggregate its sales under Rule 144) can be sold without limitation in any three (3)-month period without registration in compliance with Rule 144; or 

(c) the fifth (5th) anniversary of the consummation of the IPO. 

3. Information and Observer Rights. 

3.1 Delivery of Financial Statements. The Company shall deliver to each Major Investor, provided that the Board of Directors has
not reasonably determined that such Major Investor is a competitor of the Company: 
 (a) as soon as practicable, but in any event within
one hundred eighty (180) days after the end of each fiscal year of the Company or such later date as may be approved by the Majority Preferred Directors, (i) a balance sheet as of the end of such year, (ii) statements of income and of
cash flows for such year, and a comparison between (x) the actual amounts as of and for such fiscal year and (y) the comparable amounts for the prior year and as included in the Budget (as defined in
Section 3.1(e)) for such year, with an explanation of any material differences between such amounts and a schedule as to the sources and applications of funds for such year, and (iii) a statement of stockholders’
equity as of the end of such year, all such financial statements 

  
 15. 

 
audited and certified by independent public accountants of nationally recognized standing selected by the Company; 

(b) as soon as practicable, but in any event within forty-five (45) days after the end of each of the first three (3) quarters of
each fiscal year of the Company, unaudited statements of income and of cash flows for the portion of the fiscal year ending on the expiry of such fiscal quarter, and a comparison between (x) the actual amounts as of and for such period and
(y) the comparable amounts for the same period in the prior fiscal year and as included in the Budget, and an unaudited balance sheet and a statement of stockholders’ equity as of the end of such fiscal quarter, all prepared in accordance
with GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments and (ii) not contain all notes thereto that may be required in accordance with GAAP); 

(c) as soon as practicable, upon request by a Major Investor, a statement showing the number of shares of each class and series and
securities convertible into or exercisable for shares outstanding at the end of the most recently completed fiscal quarter, the Common Stock issuable upon conversion or exercise of any outstanding securities convertible or exercisable for Common
Stock and the exchange ratio or exercise price applicable thereto, and the number of shares of issued stock options and stock options not yet issued but reserved for issuance, if any, all in sufficient detail as to permit the Major Investors to
calculate their respective percentage equity ownership in the Company; 
 (d) as soon as practicable, but in any event within thirty
(30) days after the end of each month or such later date as may be approved by the Majority Preferred Directors, unaudited statements of income and of cash flows for such month, and an unaudited balance sheet as of the end of such month,
all prepared in accordance with GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments and (ii) not contain all notes thereto that may be required in
accordance with GAAP); 
 (e) (i) as soon as practicable, but in any event thirty (30) days before the end of each fiscal year, a
draft budget and business plan for the next fiscal year prepared on a monthly basis, including balance sheets, income statements, and statements of cash flow for such months (collectively, the “Budget”), (ii) as soon as practicable,
but in any event within fifteen (15) days after the end of each such fiscal year, a final Budget approved by the Board of Directors in accordance with Section 5.4(f) hereof, and (iii) any other budgets or revised budgets
prepared by the Company and approved by the Board of Directors, promptly following such approval by the Board of Directors; and 
 (f) such
other information relating to the financial condition, business, prospects, or corporate affairs of the Company as any Major Investor may from time to time reasonably request; provided, however, that the Company shall not be obligated under
this Section 3.1 to provide information (i) that the Company reasonably determines in good faith to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in form
acceptable to the Company) (ii), the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel, or (iii) if the Company has reasonably determined that such Major Investor is a competitor of the
Company. 

  
 16. 

 If, for any period, the Company has any subsidiary whose accounts are consolidated with those of the
Company, then in respect of such period the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries. 

Notwithstanding anything else in this Section 3.1 to the contrary, the Company may cease providing the information set forth in this
Section 3.1 during the period starting with the date thirty (30) days before the Company’s good-faith estimate of the date of filing of a registration statement if it reasonably concludes it must do so to comply
with the SEC rules applicable to such registration statement and related offering; provided that the Company’s covenants under this Section 3.1 shall be reinstated at such time as the Company is no longer
actively employing its commercially reasonable efforts to cause such registration statement to become effective. 
 3.2 Inspection.
The Company shall permit each Major Investor or its authorized representatives (provided that the Board of Directors has not reasonably determined that such Major Investor is a competitor of the Company), at such Major Investor’s
expense, to visit and inspect the Company’s properties; examine its books of account and records; and discuss the Company’s affairs, finances, and accounts with its officers, during normal business hours of the Company as may be reasonably
requested by the Major Investor; provided, however, that the Company shall not be obligated pursuant to this Section 3.2 to provide access to any information that it reasonably and in good faith considers to be a
trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in form acceptable to the Company) or the disclosure of which would adversely affect the attorney-client privilege between the Company and its
counsel. 
 3.3 Observer Rights. As long as Novalis continues to hold any shares of Preferred Stock, the Company shall invite one
(1) individual designated by Novalis (the “Novalis Observer”) to attend all meetings of its Board of Directors in a nonvoting observer capacity and, in this respect, shall give the Novalis Observer copies of all notices,
minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that the Novalis Observer shall agree to hold in confidence and trust
and to act in a fiduciary manner with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude the Novalis Observer from any meeting or portion thereof
if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest, or if Novalis or the Novalis
Observer is a competitor of the Company. 
 3.4 Confidentiality. Each Investor agrees that such Investor will keep confidential and
will not disclose, divulge, or use for any purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement (including notice of the Company’s intention
to file a prospectus or registration statement), unless such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this Section 3.4 by such Investor),
(b) is or has been independently developed or conceived by the Investor without use of the Company’s confidential information, or (c) is or has been made known or disclosed to the Investor by a third party without a breach of any
obligation of confidentiality such third party may have to the 

  
 17. 

 
Company; provided, however, that an Investor may disclose confidential information (i) to its attorneys, accountants, consultants, and other professionals to the extent necessary to
obtain their services in connection with monitoring its investment in the Company or, to the extent necessary in connection with an Investor’s tax filings, financial reporting or accounting matters (including any required filings with the SEC);
(ii) to any prospective purchaser of any Registrable Securities from such Investor, if such prospective purchaser agrees to be bound by the provisions of this Section 3.4; (iii) to any Affiliate, or current or prospective
partner, member or stockholder, or wholly owned subsidiary of such Investor in the ordinary course of business, or in connection with fund raising activity or reporting activity of the kind customarily provided with respect to investment activity
that is undertaken in the ordinary course of the business of the Investor, provided that such Investor informs such Person that such information is confidential and directs such Person to maintain the confidentiality of such information; or
(iv) as may otherwise be required by law, provided that the Investor promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure. 

3.5 Termination of Information and Observer Rights. The covenants set forth in Sections 3.1,
3.2 and 3.3 shall terminate and be of no further force or effect upon the consummation of the Qualified Initial Public Offering. 

4. Rights to Future Stock Issuances and Securities. 

4.1 Right of First Offer. Subject to the terms and conditions of this Section 4.1 and applicable securities
laws, if the Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each Preferred Stockholder. Each Preferred Stockholder shall be entitled to apportion the right of first offer hereby granted to
it among itself and its Affiliates in such proportions as it deems appropriate. 
 (a) The Company shall give notice (the “Offer
Notice”) to each Preferred Stockholder, stating (i) its bona fide intention to offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it proposes to
offer such New Securities. 
 (b) By notification to the Company within twenty (20) days after the Offer Notice is given, each
Preferred Stockholder may elect to purchase or otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion that the Common Stock issued and held, or issuable
(directly or indirectly) upon conversion or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held, by such Preferred Stockholder bears to the total Common Stock of the Company then outstanding (assuming full
conversion or exercise, as applicable, of all Preferred Stock and other Derivative Securities). At the expiration of such twenty (20) day period, the Company shall promptly notify each Preferred Stockholder that elects to purchase or acquire
all the shares available to it (each, a “Fully Exercising Investor”) of any other Preferred Stockholder’s failure to do likewise. During the ten (10) day period commencing after the Company has given such notice, each
Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in addition to the number of shares specified above, up to that portion of the New Securities for which Preferred Stockholders were entitled to subscribe
but that were not subscribed for by the Preferred Stockholders which is equal to the proportion that 

  
 18. 

 
the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of Preferred Stock and any other Derivative Securities then held, by such
Fully Exercising Investor bears to the Common Stock issued and held, or issuable (directly or indirectly) upon conversion or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held, by all Fully
Exercising Investors who wish to purchase such unsubscribed New Securities. The closing of any sale pursuant to this Section 4.1(b) shall occur within the later of one hundred twenty (120) days after the date that the
Offer Notice is given and the date of initial sale of New Securities pursuant to Section 4.1(c). 
 (c) If all New Securities
referred to in the Offer Notice are not elected to be purchased or acquired as provided in Section 4.1(b), the Company may, during the ninety (90) day period following the expiration of the periods provided in
Section 4.1(b), offer and sell the remaining unsubscribed portion of such New Securities to any Person or Persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Offer
Notice. If the Company does not enter into an agreement for the sale of the New Securities within such period, or if such agreement is not consummated within thirty (30) days after the execution thereof, the right provided hereunder shall be
deemed to be revived and such New Securities shall not be offered unless first reoffered to the Preferred Stockholders in accordance with this Section 4.1. 

(d) The right of first offer in this Section 4.1 shall not be applicable to (i) Exempted Securities;
(ii) shares of Common Stock issued in the IPO; or (iii) the issuance of shares of Series 4 Preferred to purchasers pursuant to the Purchase Agreement. 

4.2 Termination. The covenants set forth in Section 4.1 shall terminate and be of no further force or effect
upon the consummation of the Qualified Initial Public Offering. 
 5. Additional Covenants. 

5.1 Insurance. The Company shall maintain, from financially sound and reputable insurers Directors and Officers liability insurance, in
an amount not less than $3,000,000 (or such higher amount as may be agreed to by the Majority Preferred Directors) and on terms and conditions satisfactory to the Board of Directors until such time as the Board of Directors determines that such
insurance should be discontinued. The policy shall not be cancelable by the Company without prior approval by the Board of Directors, including the Majority Preferred Directors. 

5.2 Employee Agreements. The Company will cause (i) each person now or hereafter employed by it or by any subsidiary (or engaged
by the Company or any subsidiary as a consultant/independent contractor) with access to confidential information and/or trade secrets to enter into a nondisclosure and proprietary rights assignment agreement and (ii) each Key Employee to enter
into a one (1) year noncompetition and nonsolicitation agreement, substantially in the form approved by the Board of Directors. In addition, the Company shall not amend, modify, terminate, waive, or otherwise alter, in whole or in part, any of
the above-referenced agreements or any restricted stock agreement between the Company and any employee, without the approval of the Board of Directors, including the Majority Preferred Directors. 

  
 19. 

 5.3 Employee Stock. Unless otherwise approved by the Board of Directors,
including the Majority Preferred Directors, all future employees and consultants of the Company who purchase, receive options to purchase, or receive awards of shares in the capital of the Company after the date hereof shall be required to execute
restricted stock or option agreements, as applicable, providing for (i) vesting of shares over a four (4) year period, with the first twenty-five percent (25%) of such shares vesting following twelve (12) months of continued
employment or service, and the remaining shares vesting in equal monthly installments over the following thirty-six (36) months, and (ii) a market stand-off
provision substantially similar to that in Section 2.11. In addition, unless otherwise approved by the Board of Directors, including the Majority Preferred Directors, the Company shall retain a “right of first
refusal” on employee transfers until the Qualified Initial Public Offering, and shall have the right to repurchase unvested shares at cost upon termination of employment of a holder of restricted stock. 

5.4 Matters Requiring Majority Preferred Directors’ Approval. The Company hereby covenants and agrees with each of
the Investors that it shall not (and shall cause any of its direct or indirect subsidiaries to not), without approval of a majority of the Board of Directors, including the Majority Preferred Directors: 

(a) approve any sale, license, pledge, encumbrance, or other transfer of any intellectual property, other than licenses, pledges or
encumbrances in the ordinary course of business; 
 (b) enter into material contracts affecting the Company’s right to compete in the
industry in which it operates; 
 (c) enter into joint ventures or partnerships or establish
non-wholly owned subsidiaries; 
 (d) incur any additional indebtedness for borrowed money
following the date of this Agreement in excess of $1,000,000 in the aggregate; 
 (e) appoint or remove the Chief Executive Officer or the
Chief Financial Officer; 
 (f) approve the Budget (including any material amendments thereto); 

(g) change the Company’s current line of business in any material respect, enter into new lines of business or exit the current line of
business; or 
 (h) adopt or amend employment contracts or benefit plans for the Company’s senior management. 

5.5 Board Matters; Committees. Unless otherwise determined by the vote of a majority of the directors then in office, the Board
of Directors shall meet at least four (4) times per year in accordance with an agreed-upon schedule. The Company shall reimburse the non-employee directors and the Novalis Observer for all reasonable out-of-pocket travel expenses incurred (consistent with the Company’s travel policy, if any) in connection with attending meetings of the Board of Directors and
committees of the Board of Directors of which any such 

  
 20. 

 
director is a member and attending other Company events at the Company’s request. The Company will maintain, an audit and compensation committee, each of which shall consist solely of non-management directors and shall include the Majority Preferred Directors; provided, that a Preferred Director shall not be required to serve on any such committee to the extent such director is not willing
or able to so serve. The Preferred Directors shall be entitled to sit on any committee of the Board of Directors, and the board of directors (or similar body) of any subsidiary of the Company. 

5.6 Successor Indemnification. If the Company or any of its successors or assignees consolidates with or merges into any other Person
and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that the successors and assignees of the Company assume the obligations of the Company with
respect to indemnification of members of the Board of Directors as in effect immediately before such transaction, whether such obligations are contained in the Certificate of Incorporation or elsewhere, as the case may be. 

5.7 Termination of Covenants. The covenants set forth in this Section 5, except for
Section 5.6, shall terminate and be of no further force or effect upon the consummation of a Qualified Initial Public Offering. 

5.8 Additional Purchasers. The Parties to this Agreement specifically acknowledge and agree that the Company may issue additional
shares of Series 4 Preferred after the date of this Agreement pursuant to the Purchase Agreement; provided that such additional purchasers execute a counterpart to this Agreement and become a party hereto. 

6. Miscellaneous. 
 6.1
Successors and Assigns. The rights under this Agreement may only be assigned (and only with all related obligations) by a Holder to a transferee of Registrable Securities that (i) is an Affiliate of a Holder; (ii) is a
Holder’s Immediate Family Member or trust for the benefit of an individual Holder or one or more of such Holder’s Immediate Family Members; or (iii) after such transfer, holds at least 150,000 shares of Registrable Securities (subject
to appropriate adjustment for stock splits, stock dividends, combinations, and other recapitalizations); provided, however, that (x) the Company is, within a reasonable time after such transfer, furnished with written notice of the name
and address of such transferee and the Registrable Securities with respect to which such rights are being transferred; and (y) such transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and
conditions of this Agreement, including the provisions of Section 2.11. For the purposes of determining the number of shares of Registrable Securities held by a transferee, the holdings of a transferee (1) that is an Affiliate or
stockholder of a Holder; (2) who is a Holder’s Immediate Family Member; or (3) that is a trust for the benefit of an individual Holder or such Holder’s Immediate Family Member shall be aggregated together and with those of the
transferring Holder; provided further, that all transferees who would not qualify individually for assignment of rights shall have a single attorney-in-fact for
the purpose of exercising any rights, receiving notices, or taking any action under this Agreement. The terms and conditions of this Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees of the
parties. Nothing in this Agreement, express or implied, is intended to confer upon any party 

  
 21. 

 
other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly
provided herein. 
 6.2 Governing Law. This Agreement shall be governed by, and construed in accordance with, the laws of the State
of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of law. 
 6.3 Currency. All
references to currency in this Agreement are to United States dollars unless otherwise specifically indicated. 
 6.4
Counterparts; Facsimile. This Agreement may be executed and delivered by facsimile transmission or electronic mail (including in .pdf format) and in two or more counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument. 
 6.5 Titles and Subtitles. The titles and subtitles used in this Agreement
are for convenience only and are not to be considered in construing or interpreting this Agreement. 
 6.6 Notices. All notices and
other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt or: (i) personal delivery to the party to be notified; (ii) when sent, if sent by
electronic mail or facsimile during the recipient’s normal business hours, and if not sent during normal business hours, then on the recipient’s next business day; (iii) five (5) days after having been sent by registered or certified
mail, return receipt requested, postage prepaid; or (iv) one (1) business day after the business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying next-day
delivery, with written verification of receipt. All communications shall be sent to the respective parties at their addresses as set forth on Schedule A hereto, or to the principal office of the Company and to the attention
of the President or Chief Executive Officer, in the case of the Company, or to such email address, facsimile number, or address as subsequently modified by written notice given in accordance with this Section 6.6. 

6.7 Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived
(either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the holders of a majority of the Registrable Securities then outstanding, including the Series 3-4 Requisite Holders (as defined in the Certificate of Incorporation); provided that the Company may in its sole discretion waive compliance with Section 2.12(c) (and the
Company’s failure to object promptly in writing after notification of a proposed assignment allegedly in violation of Section 2.12(c) shall be deemed to be a waiver); and provided further, that any provision
hereof may be waived by any waiving party on such party’s own behalf, without the consent of any other party. Notwithstanding the foregoing, this Agreement may not be amended or terminated and the observance of any term hereof may not be waived
with respect to any Investor without the written consent of such Investor, unless such amendment, termination, or waiver applies to all Investors in the same fashion (it being agreed that a waiver of the provisions of
Section 4 with respect to a particular transaction shall be deemed to apply to all Investors in the same fashion if such waiver 

  
 22. 

 
does so by its terms, notwithstanding the fact that certain Investors may nonetheless, by agreement with the Company, purchase securities in such transaction). 

The Company shall give prompt notice of any amendment or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such
amendment, termination, or waiver. Any amendment, termination, or waiver effected in accordance with this Section 6.7 shall be binding on all parties hereto, regardless of whether any such party has consented thereto or
received notice thereof. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term, condition, or
provision. 
 6.8 Severability. In case any one or more of the provisions contained in this Agreement is for any reason held to be
invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal, or unenforceable provision shall be reformed and construed so that
it will be valid, legal, and enforceable to the maximum extent permitted by law. 
 6.9 Aggregation of Stock. All shares of
Registrable Securities held or acquired by Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves in any
manner they deem appropriate. 
 6.10 Entire Agreement. This Agreement (including any Schedules and Exhibits hereto) constitutes the
full and entire understanding and agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled. The Prior
Agreement is superseded by the terms of this Agreement. 
 6.11 Delays or Omissions. No delay or omission to exercise any right,
power, or remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such non-breaching or non-defaulting party, nor shall it be construed to be a waiver of or acquiescence to any such breach or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or
default be deemed a waiver of any other breach or default theretofore or thereafter occurring. All remedies, whether under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. 

6.12 Acknowledgment. The Company acknowledges that certain Investors and their Affiliated advisers and funds are registered investment
companies, professional investment advisers, managers and/or funds and, as such, engage in the business of venture capital investing, among other things, and therefore review the business plans and related proprietary information of many
enterprises, including enterprises which may have products or services which compete directly or indirectly with those of the Company. Nothing in this Agreement shall preclude or in any way restrict such Investors or their Affiliated advisers and
funds from investing or participating in any particular enterprise whether or not such enterprise has products or services which compete with those of the Company. The Company acknowledges and agrees that the Tekla

  
 23. 

 
Funds shall not be deemed to be competitors of the Company for purposes of this Agreement solely as a result of such activities. 

6.13 Tekla Funds. A copy of the Declaration of Trust, as amended and restated, for each of Tekla Healthcare Investors, Tekla Life
Sciences Investors, Tekla Healthcare Opportunities Fund and Tekla World Healthcare Fund is on file with the Secretary of State of The Commonwealth of Massachusetts, and notice is hereby given that this Agreement is executed on behalf of the Tekla
Funds by an officer or trustee of the Tekla Funds in his or her capacity as an officer or trustee of the Tekla Funds, and not individually and that the obligations of or arising out of this Agreement are not binding upon any of the trustees,
officers or shareholders individually but are binding only upon the assets and property of each of the respective Tekla Funds. 

[Remainder of Page Intentionally Left Blank] 

  
 24. 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	COMPANY:
	
	DECIPHER BIOSCIENCES, INC.
		
	By:	 	/s/ Tina S. Nova, Ph.D.
	Name:	 	Tina S. Nova, Ph.D.
	Title:	 	President and Chief Executive Officer

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	ALBANY PRIVATE EQUITY PTY LTD.
		
	By:	 	/s/ Peter Hall
	Name: Peter Hall
	Title: Director

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

	
	 AYOUNG JUN

	
	 /s/ Ayoung Jun

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	B.C. CAPITAL LTD.
		
	By:	 	/s/ Brian Cooper
	Name: Brian Cooper
	Title: Chairman

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	BARRY D. PLOST
		
	By:	 	/s/ Barry D. Plost

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	CD-VENTURE GMBH
		
	By:	 	/s/ Dirk Wilken
	Name: Dirk Wilken
	Title: Managing Director

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	CRG PARTNERS III – PARALLEL FUND “A” L.P.
	 BY: CRG PARTNERS III – PARALLEL FUND “A” GP L.P.

ITS: GENERAL PARTNER

	 BY: CRG PARTNERS III – PARALLEL FUND “A” GP LLC

ITS: GENERAL PARTNER

		
	By:	 	/s/ Nathan Hukill
	Name: Nathan Hukill
	Title: Authorized Signatory

  

			
	Witness:	 	/s/ Nicole Nesson
	Name:	 	Nicole Nesson

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	CRG PARTNERS III – PARALLEL FUND “B”
(CAYMAN) L.P.
	 BY: CRG PARTNERS III (CAYMAN) GP L.P.

ITS: GENERAL PARTNER

	 BY: CRG PARTNERS III GP LLC

ITS: GENERAL PARTNER

		
	By:	 	/s/ Nathan Hukill
	Name: Nathan Hukill
	Title: Authorized Signatory

  

			
	Witness:	 	/s/ Nicole Nesson
	Name:	 	Nicole Nesson

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

	
	 CRG PARTNERS III (CAYMAN) LEV AIV I L.P.

    BY: CRG PARTNERS III –(CAYMAN) GP L.P.

    ITS: GENERAL PARTNER

        BY: CRG PARTNERS III GP LLC

        ITS: GENERAL PARTNER 

 
			
		
	By:	 	/s/ Nathan Hukill

 
			
	Name:	 	Nathan Hukill

 
			
	Title:	 	Authorized Signatory

 
			
		
	Witness:	 	/s/ Nicole Nesson
	Name:	 	Nicole Nesson

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

	
	 CRG PARTNERS III (CAYMAN) UNLEV AIV I L.P.

    BY: CRG PARTNERS III –(CAYMAN) GP L.P.

    ITS: GENERAL PARTNER

        BY: CRG PARTNERS III GP LLC

        ITS: GENERAL PARTNER 

 
			
		
	By:	 	/s/ Nathan Hukill

 
			
	Name:	 	Nathan Hukill

 
			
	Title:	 	Authorized Signatory

 
			
		
	Witness:	 	/s/ Nicole Nesson

 
			
	Name:	 	Nicole Nesson

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

	
	 CRG PARTNERS III L.P.

    BY: CRG PARTNERS III GP L.P.

    ITS: GENERAL PARTNER

        BY: CRG PARTNERS III GP LLC

        ITS: GENERAL PARTNER 

 
			
		
	By:	 	/s/ Nathan Hukill

 
			
	Name:	 	Nathan Hukill

 
			
	Title:	 	Authorized Signatory

 
			
		
	Witness:	 	/s/ Nicole Nesson

 
			
	Name:	 	    Nicole Nesson

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	D PARKES OPERA INC.

 
			
		
	 By:
	 	/s/ David Parkes

 
			
	Name:	 	David Parkes

 
			
	Title:	 	Sole Director and Authorized Signatory

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	EITAN SHAPIRO

 
			
		
	By:	 	 /s/ Eitan Shapiro

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	ERIC LIEW

 
			
		
	 By:
	 	/s/ Eric Liew

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	GORDON AND LISA BENNETT

 
			
		
	 By:
	 	/s/ Gordon Bennett

 
			
	Name:	 	Gordon Bennett

 
			
		
	By:	 	/s/ Lisa Bennett

 
			
	Name:	 	Lisa Bennett

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	IAN GOLD

 
			
		
	 By:
	 	/s/ Ian Gold

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	JEFFREY ZACKON

 
			
		
	 By:
	 	/s/ Jeffrey Zackon

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	KBO HOLDINGS LTD.

 
			
		
	 By:
	 	/s/ Gordon Bennett

 
			
	Name:	 	Gordon Bennett

 
			
	Title:	 	Sole Director and Authorized Signatory

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	MARC AND MARA DWORSKY LIVING TRUST
		
	By:	 	/s/ Marc Dworsky
	Name:	 	Marc Dworsky
	Title:	 	Trustee
	
	MARC DWORSKY 
		
	By:	 	/s/ Marc Dworsky
	Name:	 	Marc Dworsky

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	MICHAEL F. CROWLEY II AND CHRISTINE N. CROWLEY

 
			
		
	By:	 	/s/ Michael F. Crowley II

 
			
	Name:	 	Michael F. Crowley II

 
			
		
	By:	 	/s/ Christine N. Crowley

 
			
	Name:	 	Christine N. Crowley

 
			
	
	 MICHAEL F. CROWLEY

 
			
		
	By:	 	/s/ Michael F. Crowley II

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	MSD HUMAN HEALTH HOLDING BV

 
			
		
	By:	 	/s/ P.R. Koopman

 
			
	Name:	 	P.R. Koopman

 
			
	Title:	 	Director

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	NOVALIS LIFESCIENCES INVESTMENTS I, L.P.

 
			
	BY:	 	NOVALIS LIFESCIENCES INVESTMENTS I GP, LLC

 
			
	ITS:	 	GENERAL PARTNER

 
			
		
	By:	 	/s/ Marijn E. Dekkers

 
			
	Name:	 	Marijn E. Dekkers

 
			
	Title:	 	Manager

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	OMER GALIN
		
	 By:
	 	/s/ Omer Galin

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	SHAPIRO SHOW LTD.
		
	By:	 	/s/ Eitan Shapiro
	Name:	 	Eitan Shapiro
	Title:	 	Chairman

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	SHMULIK ZYSMAN
		
	 By:
	 	/s/ Shmulik Zysman

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	TEKLA HEALTHCARE INVESTORS*
		
	By:	 	/s/ Daniel R. Omstead
	Name:	 	Daniel R. Omstead
	Title:	 	President

  

	*	 The name Tekla Healthcare Investors is the designation of the Trustees for the time being under a Declaration
of Trust dated February 20, 1992, as amended, and all persons dealing with Tekla Healthcare Investors must look solely to the trust property for the enforcement of any claim against Tekla Healthcare Investors, as neither the Trustees, officers
nor shareholders assume any personal liability for the obligations entered into on behalf of Tekla Healthcare Investors. 

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	TEKLA HEALTHCARE OPPORTUNITIES FUND*
		
	By:	 	/s/ Daniel R. Omstead
	Name:	 	Daniel R. Omstead
	Title:	 	President

  

	*	 The name Tekla Healthcare Opportunities Fund is the designation of the Trustees for the time being under a
Declaration of Trust dated February 20, 1992, as amended, and all persons dealing with Tekla Healthcare Opportunities Fund must look solely to the trust property for the enforcement of any claim against Tekla Healthcare Opportunities Fund, as
neither the Trustees, officers nor shareholders assume any personal liability for the obligations entered into on behalf of Tekla Healthcare Opportunities Fund. 

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	TEKLA LIFE SCIENCES INVESTORS*
		
	By:	 	/s/ Daniel R. Omstead
	Name:	 	Daniel R. Omstead
	Title:	 	President

  

	*	 The name Tekla Life Sciences Investors is the designation of the Trustees for the time being under a
Declaration of Trust dated February 20, 1992, as amended, and all persons dealing with Tekla Life Sciences Investors must look solely to the trust property for the enforcement of any claim against Tekla Life Sciences Investors, as neither the
Trustees, officers nor shareholders assume any personal liability for the obligations entered into on behalf of Tekla Life Sciences Investors. 

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	TEKLA WORLD HEALTHCARE FUND*

 
			
		
	 By:
	 	/s/ Daniel R. Omstead

 
			
	Name:	 	Daniel R. Omstead

 
			
	Title:	 	President

  

	*	 The name Tekla World Healthcare Fund is the designation of the Trustees for the time being under a Declaration
of Trust dated February 20, 1992, as amended, and all persons dealing with Tekla World Healthcare Fund must look solely to the trust property for the enforcement of any claim against Tekla World Healthcare Fund, as neither the Trustees,
officers nor shareholders assume any personal liability for the obligations entered into on behalf of Tekla World Healthcare Fund. 

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	THE MOSS FAMILY TRUST DATED DECEMBER 22, 2004

 
			
		
	By:	 	/s/ Gillian Moss

 
			
	 Name:
	 	Gillian Moss

 
			
	 Title:
	 	Trustee

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	UNITEDHEALTH GROUP VENTURES, LLC

 
			
		
	 By:
	 	/s/ Rob Webb

 
			
	Name:	 	Rob Webb

 
			
	Title:	 	President

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTOR: 

 

			
	YONGCHENG (CAYMAN) LIMITED

 
			
		
	 By:
	 	 /s/ Dong Jiaming

			
	Name:	 	Dong Jiaming

 
			
	Title:	 	Director

  

			
	YONGHUA INTERNATIONAL II L.P.

 
			
		
	 By:
	 	/s/ Huang Ting

 
			
	Name:	 	Huang Ting

 
			
	Title:	 	Authorised Signatory of the General Partner

  

			
	YH NORTH AMERICA CAPITAL L.P.

 
			
		
	 By:
	 	/s/ Huang Ting

 
			
	Name:	 	Huang Ting

 
			
	Title:	 	Authorised Signatory of the General Partner

  
 [SIGNATURE
PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 SCHEDULE A 

INVESTORS 
  

	
	 Investor Name

	Albany Private Equity Pty Ltd.
	Ayoung Jun
	B.C. Capital Ltd.
	Barry D. Plost
	Barry Shaked
	CD-VENTURE GmbH
	Cosmic Network Limited
	 CRG Partners III – Parallel Fund “A” L.P.

CRG Partners III – Parallel Fund “B” (Cayman) L.P.

CRG Partners III Cayman Lev AIV I L.P.

CRG Partners III Cayman Unlev AIV I L.P.

CRG Partners III L.P.

	D Parkes Opera Inc.
	Eitan Shapiro
	Eric Liew
	EVP Technology Fund III GmbH & Co KG
	Gordon and Lisa Bennett
	Ian Gold
	Jeffrey Zackon
	KBO Holdings Ltd.
	 Marc and Mara Dworsky Living Trust December 1, 2008

Marc Dworsky

	 Michael F. Crowley

Michael F. Crowley II and Christine N. Crowley

	MSD Human Health Holding BV
	Nathan Schaffer
	Novalis LifeSciences Investments I, L.P.
	Omer Galin
	Rostan Gamma Limited
	Sarah Marel-Schaffer
	Shapiro Show Ltd.
	Shipley Family Chatham Trust
	Shmulik Zysman
	 Tekla Healthcare Investors

Tekla Healthcare Opportunities Fund

Tekla Life Sciences Investors

Tekla World Healthcare Fund

	The Moss Family Trust dated December 22, 2004
	UnitedHealth Group Ventures, LLC
	YH North America Capital L.P.
	 Yongcheng (Cayman) Limited

Yonghua International II L.P.

  
 A-1EX-10.18

 Exhibit 10.18 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 Confidential 

Execution Copy 

SUPPLY AGREEMENT 

This SUPPLY AGREEMENT (this “Agreement”), dated as of June 7, 2019 (the “Effective
Date”), is made by and between Affymetrix, Inc., a Delaware corporation that is part of Thermo Fisher Scientific Inc., having its principal office at 3450 Central Expressway, Santa Clara, California 95051 (“Affymetrix”),
and Decipher Biosciences, Inc., a Delaware corporation with offices at 10355 Science Center Drive, Suite 240, San Diego, CA 92121 (referred to generally as “Partner,” and also as “Buyer” in Schedule B).
Affymetrix and Partner are each referred to individually as a “Party,” and together as the “Parties.” 

WHEREAS, Affymetrix, Inc. and GenomeDx Biosciences Inc. entered into that certain Powered by Affymetrix Agreement dated as of
March 6, 2014, which was amended on March 5, 2017 (the “2014 Agreement”); 
 WHEREAS, Affymetrix
was acquired by Thermo Fisher Scientific Inc. on March 31, 2016; 
 WHEREAS, GenomeDx Biosciences Inc. changed its name
to GenomeDx Inc. in connection with its re-domicile from British Columbia to Delaware in July 2018, and then changed its name to Decipher Biosciences, Inc. in January 2019; and 

WHEREAS, the Parties wish to terminate the 2014 Agreement and enter into this new Agreement as of the Effective Date. 

NOW, THEREFORE, in consideration of the mutual covenants contained herein and other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows: 
 ARTICLE I 

DEFINITIONS 

Section 1.01 Definitions. 

As used throughout this Agreement, each of the following terms shall have the respective meaning set forth below: 

“Affiliate” of a Party means any entity that directly or indirectly controls, is controlled by or is under
common control with such Party. “Control” (and, with correlative meanings, the terms “controlled by” and “under common control with”) means, in the case of a corporation, the ownership of
more than fifty percent (50%) of the outstanding voting securities thereof or, in the case of any other type of entity, an interest that results in the ability to direct or cause the direction of the management and policies of such entity or the
power to appoint more than fifty percent (50%) of the members of the governing body of the entity, or if not meeting the preceding requirement, any company owned or controlled by or owning or controlling a Party at the maximum control or ownership
right permitted in the country where such Party exists. 
 “Affymetrix Intellectual Property Rights” means
all Intellectual Property Rights owned or controlled as of the Effective Date or thereafter during the Term by Affymetrix (exclusive of Affiliates) 

 
that would be infringed, absent a license, by the manufacture, import, use, sale or offer for sale of Diagnostic Products or Diagnostic Services in the Territory. 

“Affymetrix Products” means Arrays, reagents, and any other products sold to Partner by Affymetrix pursuant
to this Agreement. 
 “Array” means the [***], supplied to Partner by Affymetrix, and any future version of
such product. 
 “Blanket PO” has the meaning set forth in Section 3.01. 

“Cap” has the meaning set forth in Section 5.04. 

“Change of Control” of a Party shall mean if: (i) any third party acquires directly or indirectly the
beneficial ownership of any voting security of such Party, or if the percentage ownership of such person or entity in the voting securities of such Party is increased through stock redemption, cancellation or other recapitalization, and immediately
after such acquisition or increase such third party is, directly or indirectly, the beneficial owner of voting securities representing more than fifty percent (50%) of the total voting power of all of the then- outstanding voting securities of such
Party, except in connection with any change in domicile or in an equity financing transaction; (ii) a merger, consolidation, recapitalization, or reorganization of such Party is consummated, other than any such transaction which would result in
stockholders or equity holders of such Party or an Affiliate of such Party immediately prior to such transaction owning at least fifty percent (50%) of the outstanding securities of the surviving entity (or its parent entity) immediately following
such transaction; or (iii) an agreement for the sale or disposition by such Party of all or a substantial portion of such Party’s assets, other than to an Affiliate. 

“Confidential Information” has the meaning set forth in Section 5.01. 

“Diagnostic Product” means a product that is: (a) developed by Partner using the Affymetrix Products or
into which a Affymetrix Product is incorporated, and (b) marketed and sold solely under a Partner-branded label, with such product to be: (i) used for the testing of human patients and approved for use and distribution by the relevant
Regulatory Authorities, if applicable; and (ii) used and distributed in accordance with all laws and regulations of the jurisdictions in which it is being used and distributed. 

“Diagnostic Service” means, pursuant to approval by the FDA, CLIA or other relevant Regulatory Authorities
(as defined in Schedule C) for the jurisdictions in which the Diagnostic Product is being used if applicable and/or required, marketed or placed into commercial distribution, and in accordance with all laws and regulations governing such
service: (i) receiving a biological sample directly from a caregiver; (ii) applying the sample to the Diagnostic Product; reading and analyzing the experimental results; and (iv) providing, if deemed appropriate by the laboratory
performing the test, the diagnostic results directly back to the same caregiver for use in the Field. 
 “Disclosing
Party” has the meaning set forth in Section 5.01. 
 “Field” as of the Effective Date, means
the screening, detection and prognosis of cancer. 
 “Intellectual Property Rights” means legally
enforceable rights in intangible property in the form of patents, pending patent applications, trademarks, copyrights, trade secrets, know how, mask works, and 

  

[***]=CONFIDENTIAL TREATMENT REQUESTED 

 
 2 

 
other proprietary information including without limitation, specifications, data, technical, commercial, financial, regulatory and other confidential information, or any other form of
intellectual property as protected by law. 
 “Instrument” means either (i) the [***], or (ii) [***],
which is FDA-cleared, CE-IVD marked and regulatory cleared in multiple countries. 

“Payment Plan” has the meaning set forth in Section 5.11. 

“Probe” means a single species of oligonucleotide designed to be affixed to one or more arrays to detect one
or more analytes or the description or disclosure of such an oligonucleotide. 
 “Receiving Party” has the
meaning set forth in Section 5.01. 
 “Release Order” has the meaning set forth in Section 3.01.

 “Term” has the meaning set forth in Section 5.03. 

“Territory” means worldwide. 

[***] 

Other capitalized terms have the meaning set forth in the body of this Agreement. 

ARTICLE II 
 DIAGNOSTIC PRODUCTS
AND SERVICES 
 Section 2.01 Diagnostic Rights. 

Affymetrix hereby grants Partner a non-exclusive,
non-sublicensable, non-transferable license, subject to the exclusions set forth below, in the Territory to the Affymetrix Intellectual Property Rights to:
(i) make, have made, use, market, sell, offer for sale, import and distribute (including via multiple levels of distributors) Diagnostic Products for use in the Field; and (ii) provide Diagnostic Service(s) in the Field (but excluding any
right to make or have made Arrays. Notwithstanding the foregoing, this Agreement does not convey to Partner any right to (i) make or have made any Affymetrix Product or any component thereof, or (ii) sell Affymetrix Products on a
stand-alone basis, as a component of or bundled with any products or services except as part of Diagnostic Products and Diagnostic Services. 

  

[***]=CONFIDENTIAL TREATMENT REQUESTED 

 
 3 

 Section 2.02 Licenses of Third Party Intellectual
Property Rights, Content or Applications. 
 Partner will be solely and exclusively responsible for securing all licenses
necessary to utilize any third party Intellectual Property Rights, or applications for use in connection with the Diagnostic Products and Diagnostic Services, and Partner will be solely and exclusively responsible for assuming all financial
obligations associated with such licenses entered into by Partner, including payment of any upfront fees, milestone payments, and/or royalties; and Partner will be responsible for granting licenses to third parties that may be required to enable
such third parties to use Partner’s Intellectual Property Rights, or applications in connection with the Diagnostic Products and Diagnostic Services. 

Section 2.03 Partner Intellectual Property Rights. 

All Intellectual Property Rights of Partner existing at the time of the Effective Date and coming into existence thereafter
shall remain the property of Partner and this Agreement does not effectuate any transfer of such Intellectual Property Rights to Affymetrix nor shall Affymetrix claim any right or title to such Intellectual Property Rights as a result of this
Agreement. 
 Section 2.04 Support for Partner. 

Affymetrix covenants to Partner that Affymetrix will support, and make available for use and sale, both Arrays and the
Instruments used in connection with such Arrays in a manner consistent with the level of support provided to Affymetrix’s diagnostic instrument partners generally and on Affymetrix’ customary terms and conditions, for the Tenn.
Notwithstanding anything to the contrary, and for the purpose of clarification, the Parties acknowledge and agree that no right to resell, transfer or distribute any Instrument is granted under this Agreement. 

Section 2.05 Shipment of Arrays to [***]. 

Pursuant to Section 12 of the Affymetrix Terms and Conditions of Sale attached as Schedule B, Affymetrix agrees to
allow Partner to ship Arrays to [***]. Affymetrix hereby authorizes [***] to use Partner’s Diagnostic Products incorporating the Decipher Arrays solely for the purpose of [***]. [***] 

If Affymetrix discovers that [***] is using an Array for any other purpose, Affymetrix will notify the Partner and the Partner
will have [***] days from such notice to remedy the situation or the Partner’s right to ship Arrays to [***] may be revoked by Affymetrix. 

Partner represents and warrants that: [***]. 

  

[***]=CONFIDENTIAL TREATMENT REQUESTED 

 
 4 

 For purposes of clarification, Partner [***] is the purchaser of all Arrays
supplied under this Agreement. Partner acknowledges that, as the purchaser, it must manage any warranty claims related to an Array that Partner has shipped to [***]. 

ARTICLE III 
 AFFYMETRIX PRODUCT
SUPPLY 
 Section 3.01 Product Orders. 

Partner shall place a Blanket Purchase Order (“Blanket PO”) for the balance of calendar year 2019 within ten
(10) days of the Effective Date. 
 Partner shall place a Blanket PO for calendar year 2020 by [***], and for
subsequent calendar years during the Term by [***] of the previous calendar year. 
 Each Blanket PO shall contain the
following information: (a) minimum annual quantity of Arrays and reagents in accordance with Schedule A, (b) forecasted quantities per month, and (c) a schedule of forecasted shipment release dates. Notwithstanding the
foregoing, the Blanket PO for the balance of calendar year 2019 shall be for a minimum of [***] Arrays, and the first scheduled shipment date cannot be less than [***] days from the date of the Blanket PO. 

Partner shall place release orders under each Blanket PO in accordance with the forecasted monthly quantities and scheduled
shipment dates set forth in each Blanket PO for Affymetrix Products such that all Arrays and reagents are delivered within the calendar year for that Blanket PO (each, a “Release Order”). Each Release Order shall be sent by written
or electronic purchase order to Affymetrix. Affymetrix shall be obligated to accept and fill all Release Orders for Affymetrix Products to the extent that they are in accordance with the Blanket PO, as defined above. Affymetrix will use commercially
reasonable efforts to fulfill any additional purchase orders that exceed the Blanket PO, or inform Partner of any anticipated delays, in a timely manner. Partner may purchase any Array under this Agreement for any Affiliate or diagnostic laboratory
performing the Diagnostic Services on behalf of Partner. 
 Section 3.02 Supply of Arrays. 

Affymetrix will manufacture the Arrays in a facility that adheres to Quality Management System Requirements (ISO 13485:2003)
under current Good Manufacturing Practices (cGMP), 21 C.F.R. Sec. 820. 
 Section 3.03
[Intentionally omitted]. 
 Section 3.04 Terms and Conditions of Sale. 

The Terms and Conditions of Sale for the supply of Affymetrix Products hereunder are attached hereto as Schedule B.
Notwithstanding anything to the contrary in Schedule B: (a) Partner will pre-pay for the Affymetrix Products ordered under this Agreement until Partner has paid all amounts due under the Payment
Plan attached as Schedule F, after which time Partner will pay for Affymetrix Products 

  

[***]=CONFIDENTIAL TREATMENT REQUESTED 

 
 5 

 
within [***] days of the date of the invoice, and (b) Affymetrix Products will be shipped [***]. 

Section 3.05 Force Majeure. 

In the event that either Party is prevented from performing any of its obligations under this Agreement (except for
Partner’s payment obligations) due to any cause beyond the reasonable control of such Party, and such Party shall have used all reasonable efforts to avoid, or mitigate the effects, of such occurrence, such Party shall promptly provide written
notice to the other Party describing such circumstances, and thereupon the affected Party’s performance shall be excused and the time for performance shall be extended for the period of delay or inability to perform due to such occurrence. 

Section 3.06 Product Discontinuation. 

In the event that Affymetrix decides to discontinue the manufacture of either Instrument, Affymetrix will provide Partner at
least [***] written notice of its intent to discontinue the sale of such Instrument, and Affymetrix will continue to offer service and support for such Instrument for [***] after the date of discontinuation. 

ARTICLE IV 
 PURCHASE COMMITMENTS;
PAYMENT 
 Section 4.01 Product Purchase and Supply Commitments. 

Partner will purchase Arrays and other Affymetrix Products for use in the Field at the pricing as set forth on Schedule
A. 
 As stated in Section 3.01, Partner will place Release Orders under each Blanket PO such that all Arrays are
delivered within the calendar year for that Blanket PO. If Partner fails to purchase the total quantity of Arrays set forth in any Blanket PO within that calendar year, Affymetrix will invoice Partner for the difference between the actual price paid
and the total price that would have been paid had Partner purchased the total quantity of Arrays set forth in the Blanket PO. 

Section 4.02 Price Adjustment for Affymetrix Products. 

Affymetrix will provide Partner with [***] days’ written notice of any price adjustments made in accordance with Schedule
A. 
 Section 4.03 Regulatory Issues. 

Partner and Affymetrix hereby agree to comply with their respective obligations under the Regulatory Terms and Conditions
attached hereto as Schedule C. 
 Section 4.04 Taxes. 

  

[***]=CONFIDENTIAL TREATMENT REQUESTED 

 
 6 

 Any tax that is owed by Affymetrix or its Affiliates by reason of the
execution or the performance of this Agreement and that is required to be paid or withheld by Partner under US law, including income taxes (other than Affymetrix’ income taxes), stamp taxes, registration taxes or fees, turnover taxes, or
withholding taxes, shall be withheld from any payments due to Affymetrix pursuant to this Agreement and paid when due by Partner or its Affiliates on behalf of Affymetrix or its Affiliates to the appropriate governmental authority. Payments made by
Partner to Affymetrix for Affymetrix Products pursuant to this Agreement shall be reduced by the amount of tax paid by Partner on behalf of Affymetrix or its Affiliates, and Partner or its Affiliate shall furnish Affymetrix or its Affiliates with
proof of payment of such tax, together with official or other appropriate evidence issued by the appropriate governmental authority, sufficient to enable Affymetrix or its Affiliates to support a claim in respect of any sum so withheld. Any such tax
required to be paid or withheld shall be an expense of and borne by Affymetrix or its Affiliates. 
 ARTICLE V 

MISCELLANEOUS 

Section 5.01 Confidential Information. 

Neither Party shall disclose to any third party any Confidential Information of the other, nor use the Confidential Information
of the other, for any purpose other than exercising its rights or carrying out its obligations under this Agreement. Each Party shall ensure that its and its Affiliates’ employees, officers, representatives and agents do not disclose to third
parties any Confidential Information of the other, and do not use the Confidential Information of the other for any purpose other than exercising its rights or carrying out its obligations under this Agreement. Upon the termination of this
Agreement, each Party shall return to the other or destroy all Confidential Information in its possession except such Confidential Information stored on such Party’s electronic backup system; provided that each Party may retain one copy for
archival purposes only. Each party hereto may disclose Confidential Information of the other Party to the extent such disclosure is (i) necessary for complying with applicable governmental laws or regulations of governmental or other agencies
(including, but not limited to, the United States Food and Drug Administration, the United States Securities and Exchange Commission or the National Association of Securities Dealers); (ii) necessary for complying with a court order;
(iii) otherwise required to be submitted to tax or other governmental authorities; or (iv) to existing or potential acquirers or merger candidates; sub-licensees or collaborators; auditors;
attorneys; investment bankers; existing or potential investors, venture capital firms or other financial institutions or investors for purposes of obtaining financing; or Affiliates, each of whom prior to disclosure must be bound by obligations of
confidentiality and non-use at least equivalent in scope to those set forth in this Agreement; provided that, in the case of (i)-(iii) above, if a Party is required to make any such disclosure, it will give
reasonable advance notice to the other Party of such disclosure and will use its commercially reasonable efforts to secure confidential treatment of such information in consultation with the other Party prior to disclosure (whether through
protective orders or otherwise) and will in any event disclose only the minimum necessary to comply with such requirements. 

“Confidential Information” means all proprietary and confidential information and materials of a Party that
is disclosed or made available by observation or analysis by or on behalf of such Party (the “Disclosing Party”) to the other Party (the “Receiving Party”), and which the Disclosing Party either: (i) marks as
confidential or proprietary at the time of disclosure; or (ii) in the case of verbal disclosures, identifies as confidential or proprietary at the time of disclosure and confirms the same in writing within thirty (30) calendar days of
disclosure; provided, however, that a failure to so mark or identify shall not affect in any manner the confidential nature or status of information disclosed by Discloser or Recipient’s obligations to keep such Confidential Information
secret and confidential as provided hereunder. 

  
 7 

 Confidential Information includes, but is not limited to: business, financial and technical
information, the terms of this Agreement, designs, formulations, methods, techniques, methodology, equipment, data, reports, laboratory notebooks, know-how, sources of supply, Partner and supplier lists,
patent strategy and business plans, information concerning products in development; provided that “Confidential Information” shall not include information which: (i) was known to the Receiving Party at the time it was disclosed
free of any obligation of non-disclosure, as evidenced by written records existing at the time of disclosure; (ii) is, at the time of disclosure, or later becomes publicly known under circumstances
involving no breach of this Agreement or the breach of any other agreement; (iii) lawfully and in good faith becomes available from a third party who has the right to disclose it; or (iv) was independently created by personnel of the
Receiving Party without any reference to the Disclosing Party’s Confidential Information, as evidenced by written records. The disclosure of Confidential Information hereunder shall not result in any right or license to the Receiving Party for
use or exploitation of such information. Each Receiving Party’s obligations with respect to the Confidential Information of the Disclosing Party, including Confidential Information shared under the 2014 Agreement, shall survive for [***]
following the termination or expiration of this Agreement. 
 Section 5.02 Use of Name; Public
Statements. 
 Except as set forth in this Agreement, neither Party shall use Confidential Information of the other Party
in any publication, press release, promotional material or other form of publicity without the prior written approval of such other Party in each instance. The restrictions imposed by the foregoing shall not prohibit either Party from making any
disclosure identifying the other Party that is required by applicable law. Each Party shall have the right to issue press releases and to make other public disclosures, presentations or publications with respect to this Agreement (pursuant to
filings with the Securities and Exchange Commission or otherwise); provided, however, that no such press release or other public disclosure, presentation or publication shall disclose any Confidential Information of the other Party without the prior
written consent of such other Party. The Parties agree to consult with each other reasonably and in good faith with respect to the text and timing of the initial press release regarding this Agreement, if any, and any subsequent press releases or
other disclosures prior to the issuance thereof, provided that a Party may not unreasonably withhold consent to such releases or disclosures, and that either Party may issue such press releases or make such disclosures as it determines, based on
advice of counsel, are reasonably necessary to comply with applicable laws or for appropriate market disclosure. In addition, following the initial press releases announcing this Agreement, either Party shall be free to disclose, without the other
Party’s prior written consent, the existence of this Agreement, the identity of the other Party and those terms of the Agreement which have already been publicly disclosed in accordance herewith. 

Section 5.03 Term and Termination. 

Term. Unless earlier terminated in accordance with this Section 5.03, this Agreement shall remain in effect until
December 31, 2023 (the “Initial Term”). Thereafter, this Agreement will renew for an additional four calendar years (“Renewal Term”), unless one Party gives the other Party written notice of its intent not to
renew at least six months prior to the expiration of the Initial Term. The Initial Term combined with the Renewal Term, if any, is referred to as the “Term.” 

Material Breach. In the event of a material breach by either Party of the terms of this Agreement, the other Party will
have the right to send written notice to the allegedly breaching Party identifying such breach. If a Party receives notice of material breach and such breaching Party fails to cure such breach within forty-five (45) days after giving such
breaching Party written notice by express or 

  

[***]=CONFIDENTIAL TREATMENT REQUESTED 

 
 8 

 
registered mail (or within ten (10) days’ notice in the event such breach is solely based upon the breaching Party’s failure to pay any amounts due hereunder), return receipt
requested, the non-breaching Party may terminate this Agreement by delivering written notice of termination to the breaching Party. Such forty-five (45) day or ten (10) day period shall be tolled during the pendency of any legal action in
which a Patty is disputing the existence of a material breach. 
 Failure to Supply. Partner may terminate this
Agreement immediately upon ninety (90) days prior written notice to Affymetrix in the event Affymetrix fails to deliver to Partner at least [***] of the quantity of Affymetrix Products ordered as part of the Blanket PO for [***] consecutive
quarters. 
 Government Action. Either Party may terminate this Agreement immediately upon written notice to the
other Party if Affymetrix has received written communication from any governmental authority or court stipulating the cessation of the production or sale of the Arrays. Partner may terminate this Agreement immediately upon written notice to
Affymetrix if it decides, or is required by any governmental authority, to cease all commercialization of Diagnostic Products and Diagnostic Services. For purposes of this Section, Partner may terminate this Agreement upon ninety
(90) days’ written notice to Affymetrix if Partner decides to cease or suspend commercialization of Diagnostic Products or Diagnostic Services as a result of a material reduction in Medicare, Medicaid or other applicable third party payor
reimbursement rates. 
 Termination by Partner. Partner may terminate this Agreement upon ninety (90) days prior
written notice to Affymetrix for any reason. 
 Survival of Obligations upon Expiration or Termination. Upon the
expiration of this Agreement, or termination of this Agreement upon any of the grounds set forth above in the sub-sections entitled Material Breach, Failure to Supply, Government Action and Termination By
Partner, all rights and obligations of the Parties shall cease to have effect immediately provided that the following sections of this Agreement shall survive: Sections 3.04, 4.01 and 4.04, Article 5 (Miscellaneous), Article 1 Definitions, and such
other provisions of this Agreement to the extent necessary to give meaning to the abovementioned provisions. Termination or expiration of this Agreement shall not affect any rights or liabilities of either Party which may have accrued up to the date
of such termination or expiration. Upon termination of this Agreement, Partner agrees to purchase all inventory on-hand (built per a PO from Partner and no greater than the amount in such PO) associated with
the supply of the Affymetrix Products pursuant to this Agreement at the time of the notification. 

Section 5.04 Indemnity. 

Affymetrix shall indemnify and hold harmless Partner, its Affiliates and its and their officers, directors, employees, agents
and representatives against any third party suit or proceeding brought against Partner or its Affiliates and its and their officers, directors, employees, agents and representatives to the extent based on (i) a claim that Affymetrix Product
directly infringes a valid and enforceable patent, copyright or trade secret right that exists as of the Effective Date in the United States, or (ii) Affymetrix’s breach of its obligations or warranties under this Agreement, and Affymetrix
shall pay damages and costs finally awarded against Partner resulting therefrom and reasonable costs of investigation or settlement and legal fees and accounting expenses, if any, subject to the Cap (defined below); provided that Partner notifies
Affymetrix in writing within thirty (30) calendar days of any claim or suit being made or brought and 

  

[***]=CONFIDENTIAL TREATMENT REQUESTED 

 
 9 

 
notified to Partner, and Partner gives Affymetrix authority to defend or, upon consultation with Partner, settle any such suit or proceeding, and all reasonably requested information, and
assistance necessary to settle or defend such suit or proceeding. 
 Affymetrix shall not be bound in any manner by any
settlement made without its prior express written consent. In the event that an Affymetrix Product is held to infringe as set forth above, and its use is enjoined, Partner may (a) terminate this Agreement without any further payment or
obligation to Affymetrix or (b) request that Affymetrix either obtain for Partner the right to continue using such affected Affymetrix Product, modify it to become non-infringing, or grant Partner a
credit and accept return of such unused Affymetrix Product. Notwithstanding the foregoing, Affymetrix will have no liability hereunder to the extent that the alleged or actual infringement arises: (1) from use of the Affymetrix Product in a
manner not authorized by Affymetrix in Section 2.01; (2) from combination of the Affymetrix Product with any product not supplied by Affymetrix under this Agreement; or (3) from any addition to or modification of the Affymetrix Product not
specified by Affymetrix. Further, Affymetrix will have no liability to the extent the allegedly infringing activity: (4) results from the particular Probe sequences represented on an Array; (5) results from a Diagnostic Product or a
Diagnostic Service (and would not have resulted from the Affymetrix Product alone or the procedures for use of such Affymetrix Product as specified by Affymetrix); or (6) occurs after Affymetrix has provided Partner with a design or work around
that is satisfactory to Partner or a license at Affymetrix’s cost. 
 In no event shall Affymetrix’s aggregate,
cumulative liability arising out of or relating to this Agreement (including Affymetrix’s indemnity obligations described in this section), exceed the amount of all payments made by Partner under this Agreement for the purchase of Affymetrix
Products and Commissions during the Term (the “Cap”); provided, however, that the Cap shall not apply with respect to any liability arising out of Affymetrix’s gross negligence or willful misconduct. The Cap is cumulative but
shall not include expenses incurred by Affymetrix in connection with its own legal fees. The existence of one or more claims or suits will not enlarge the Cap. Partner shall indemnify and hold harmless Affymetrix and its Affiliates and its and their
officers, directors, employees, agents and representatives for third party claims arising from Partner’s commercialization of Diagnostic Products or Diagnostic Services and any damages (including reasonable costs of investigation or settlement
and legal fees and accounting expenses) resulting therefrom subject to the Cap, except to the extent such claims or damages result from Affymetrix’ s negligence, willful misconduct, or breach of this Agreement. 

THE FOREGOING PROVISIONS OF THIS SECTION STATES THE ENTIRE LIABILITY AND OBLIGATION OF THE PARTIES, AND THE EXCLUSIVE REMEDY
OF PARTNER AND ITS AFFILIATES, WITH RESPECT TO ANY ALLEGED OR ACTUAL INFRINGEMENT OF INTELLECTUAL PROPERTY RIGHTS, AND ARE IN LIEU OF ALL WARRANTIES OF NON-INFRINGEMENT, EXPRESS OR IMPLIED. 

Section 5.05 Liability Limitation. 

EXCEPT TO THE EXTENT CAUSED BY A PARTY’S GROSS NEGLIGENCE OR WILLFUL MISCONDUCT, EACH PARTY AND ITS REPRESENTATIVES SHALL
HAVE NO LIABILITY FOR ANY LOSS OF USE OR PROFITS, PROCUREMENT OF SUBSTITUTE GOODS OR ANY INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL, PUNITIVE OR EXEMPLARY DAMAGES OF ANY KIND, HOWEVER CAUSED AND REGARDLESS OF FORM OF ACTION WHETHER IN CONTRACT,
TORT (INCLUDING NEGLIGENCE), STRICT PRODUCT LIABILITY OR OTHERWISE, EVEN IF A PARTY OR ITS REPRESENTATIVE HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. AS TO ANY AFFYMETRIX 

  
 10 

 
LIABILITY NOT LEGALLY SUBJECT TO THE FOREGOING, AFFYMETRIX LIABILITY SHALL NOT EXCEED THE CAP EXCEPT TO THE EXTENT CAUSED BY AFFYMETRIX’S GROSS NEGLIGENCE OR WILLFUL MISCONDUCT. PARTNER
UNDERSTANDS AND HEREBY AGREES THAT THE RISKS OF LOSS HEREUNDER ARE REFLECTED IN THE PRICE OF THE FINANCIAL TERMS OF THIS AGREEMENT AND THAT THESE TERMS WOULD HAVE BEEN DIFFERENT IF THERE HAD BEEN A DIFFERENT ALLOCATION OF RISK. 

Section 5.06 Insurance. 

Partner agrees to procure and maintain in full force and effect throughout the Term, valid and collectible insurance policies
in connection with its activities as contemplated hereby which policies shall provide for the following types of and amounts of coverage as set forth on Schedule D attached hereto. Partner shall give Affymetrix at least thirty
(30) calendar days’ prior written notice of any policy cancellation. Upon ten (10) days written request from Affymetrix, Partner shall provide to Affymetrix a certificate of coverage or other written evidence reasonably satisfactory
to Affymetrix of such insurance coverage. Each of Partner’s liability policies required under this Section 5.06 shall name Affymetrix, and such other entities or persons as Affymetrix may designate, as an additional insured. Such policies
shall be primary insurance to any other insurance that may be available to Affymetrix. Any other insurance available to Affymetrix shall be non-contributing with and in excess to such insurance. 

Section 5.07 Assignment. 

Neither this Agreement nor any rights under this Agreement may be assigned or otherwise transferred by either Party, in whole
or in part, including by way of sale of assets, merger or consolidation without the prior written consent of the other Party other than: (i) to an Affiliate of such Party that assumes all rights and duties thereunder and is at least as
creditworthy as the assigning Party; or (ii) in connection with a Change of Control of a Party (to include the disposition of all or substantially all of such Party’s diagnostic business). 

Section 5.08 Governing Law. 

This Agreement, including all matters of construction, validity and performance shall be governed by and construed and enforced
in accordance with the laws of the State of California without regard to its conflict of laws rules and notwithstanding the actual residence of the Parties. 

Section 5.09 Arbitration. 

All disputes, differences of opinion, or controversies which may arise between the Parties out of or in relation to or in
connection with this Agreement or the breach thereof, shall be finally settled by binding arbitration in San Diego, California under the rules of American Arbitration Association in force at the time. The arbitration shall be conducted by three
(3) arbitrators selected in accordance with the rules of the AAA and the Parties shall use commercially reasonable efforts to complete the arbitration proceedings within three (3) months. Notwithstanding the foregoing, all disputes with
respect to: (a) the validity or infringement of patent rights of either Party, and (b) satisfaction of payment obligations, shall be subject to applicable federal court jurisdiction and not be subject to the arbitration proceedings set
forth in this Section 5.09. 

  
 11 

 Section 5.10 Schedules. 

Schedules A-F are hereby incorporated by reference. In the event of a conflict
between the terms set forth in the main body of this Agreement and the terms set forth in a Schedule, the terms of the main body of the Agreement will prevail. 

Section 5.11 Termination of 2014 Agreement. 

The Parties agree that, concurrent with the commencement of this Agreement on the Effective Date, the 2014 Agreement shall
terminate by mutual consent. Such termination shall be automatic without the need to be further evidenced in writing. The Parties agree to cooperate in good faith in managing and resolving any operational issues related to the transition from the
2014 Agreement to this Agreement. Affymetrix hereby releases Partner from its obligation under the last sentence of Section 5.03 of the 2014 Agreement (Obligations Upon Termination) to purchase all inventory on-hand (built per a PO from
Partner and no greater than the amount in such PO) associated with the supply of Affymetrix Products pursuant to the 2014 Agreement. 

Survival of Payment Obligations under 2014 Agreement. Notwithstanding the termination of the 2014 Agreement,
Partner’s outstanding payment obligations under the 2014 Agreement survive and are not extinguished, released or otherwise impaired by the termination of the 2014 Agreement. Such outstanding payment obligations, and the schedule for paying
them, are set forth in the Payment Plan, which is attached to this Agreement as Schedule F, and is hereby incorporated by reference (“Payment Plan”). Partner hereby affirms the amounts due as set forth in the Payment Plan,
and agrees to pay them in accordance with the schedule set forth in Schedule F. Partner acknowledges and agrees that any outstanding payment obligations under the 2014 Agreement that are not satisfied by Partner’s adherence to the
Payment Plan (or by other means mutually agreed to by the Parties in writing) are and shall remain fully enforceable by Affymetrix in accordance with the terms of this Agreement. 

[Signatures follow] 

  
 12 

 IN WITNESS WHEREOF, the Parties hereto intending legally to be bound hereby,
have each caused this Agreement to be duly executed as of the Effective Date. 
  

									
	AFFYMETRIX, INC., part of Thermo Fisher Scientific Inc.	 		 	 DECIPHER BIOSCIENCES, INC.

					
	 By:
	 	 /s/ Will Kruka
	 		 	 By:
	 	 /s/ Brent Vetter

	 Name:
	 	 Will Kruka
	 		 	 Name:
	 	 Brent Vetter

	 Title:
	 	 VP/GM
	 		 	 Title:
	 	 CFO

	 Date:
	 	 6/10/2019
	 		 	 Date:
	 	 6/7/2019

  
 13 

 SCHEDULE A 

PRODUCT PRICES 
  

			
	Pricing for Arrays	  	[***]
		
	 Reagents
	  	[***]

  

[***]=CONFIDENTIAL TREATMENT REQUESTED 

 
 14 

 SCHEDULE B 

Affymetrix 
 Terms and Conditions
of Sale 
 1. General. These Terms and Conditions of Sale (“Terms and Conditions”) shall govern the sale and license to the
original purchaser (“Buyer”) of probe arrays, assays, reagents, instruments, software, and other products and related services (“Products”) from Affymetrix, one of its subsidiaries or authorized sellers named on the invoice or
acknowledgement (Affymetrix, Inc. or any of its subsidiaries named on the invoice is referred to here as “Affymetrix”). These Terms and Conditions shall replace and supersede any current or future purchase orders or similar forms that are
not mutually signed by Affymetrix and Buyer. Purchase orders, once accepted by Affymetrix, are not subject to cancellation or modification by Buyer without Affymetrix’ written consent. 

2. Price. 
 (a) For Deliveries
Outside Europe: Prices exclude all insurance, freight, taxes, fees, duties and levies, which shall be payable by Buyer. 
 (b) For
Deliveries Within Europe: Prices include all insurance, duties and levies, unless stated otherwise on the quotation or invoice. Freight and handling fees will be prepaid by Affymetrix and added to the invoice for reimbursement by Buyer. 

3. Delivery. Products will be packed in Affymetrix’ standard shipping packages. Affymetrix may make partial deliveries. Affymetrix will
ship via carrier selected by Affymetrix. Delivery dates set forth on a purchase order accepted by Affymetrix are subject to change and are predicated on conditions existing at that time. Affymetrix does not guarantee any delivery dates and shall not
be responsible for any loss or damage of any kind or nature whatsoever caused by any delay in delivery irrespective of the cause of such delay. 

(a) For Deliveries Outside Europe: Tender will be FCA shipping point. Title (except for software, in which case Affymetrix shall retain title)
and risk of loss or damage will pass to Buyer upon delivery of the Products to the carrier. 
 (b) For Deliveries Within Europe: Products
shall be Delivered Duty Paid Excluding VAT (DDP Ex VAT) to the Buyer’s site and the Buyer will be the importer for the Products and be responsible for paying VAT or similar taxes within the Buyer’s country. Title (except for software, in
which case Affymetrix shall retain title) and risk of loss or damage will pass to Buyer upon delivery of the Products to the carrier. 
 4.
Rejection. Any claims for damaged, missing or defective Product must be reported in writing to Affymetrix by Buyer within five (5) days from the date of receipt of Product. For any valid claim made, Affymetrix shall repair or replace the
Product. The foregoing shall be Buyer’s sole and exclusive remedy for damaged or missing Products, and, except for express warranty rights, for defective Products. 

5. Payment. Buyer will be invoiced at the time of shipment of each Product. Buyer shall make payment in full within thirty (30) days of
the date of the invoice. Late payments may incur a charge at the rate of one and one-half percent (1.5%) percent per month, or the maximum allowed by law, whichever is less. Further shipment of Products may be
declined without advance notice if Buyer fails to make any payment when due, or if the financial condition of Buyer becomes unsatisfactory to Affymetrix. Affymetrix may elect to retain a security interest in all Products sold to Buyer to secure all
of Buyer’s obligations to Affymetrix under these Terms and Conditions, and Buyer will execute any documents necessary to create and perfect this interest. Sales by Affymetrix shipped outside the U.S. may require payment on an irrevocable letter
of credit reasonably acceptable to Affymetrix. 
 6. Limited Warranty. 

 

	 	•	 	 For new instruments, Affymetrix warrants only to Buyer for the period that is the shortest of
(i) thirteen (13) months from the date of shipping; (ii) one (1) year from the date of installation; or (iii) the shortest period specified in the Affymetrix sales quote for limited-life parts, that the operating software and
instruments are free from defects in material and workmanship and conform to Affymetrix’ published specifications in all material respects. 

  

	 	•	 	 For refurbished instruments, Affymetrix warrants only to Buyer for a period that is the shortest of (i) one-hundred twenty (120) days from shipment; (ii) ninety (90) days from the date of installation; or (iii) the shortest period specified in the Affymetrix sales quote for limited-life parts,
that the operating software and instruments are free from defects in material and workmanship and conform to Affymetrix’ published specifications in all material respects. 

 

	 	•	 	 For used instruments, Affymetrix warrants only to Buyer for the period that is the shortest of (i) thirty
(30) days from date of shipment: (ii) twenty (20) days from the date of installation or (ii) the shortest period specified in the Affymetrix sales quote for limited-life parts, that the instruments and operating software are free from
defects in material and workmanship and conform to Affymetrix’ published specifications in all material respects. 

  

	 	•	 	 For all instruments, warranty service will be provided pursuant to Affymetrix’ standard service terms and
conditions enumerated therein. Affymetrix’ sole and exclusive liability (and Buyer’s sole and exclusive remedy) under the foregoing warranty shall be the repair or replacement of instruments, as solely determined by Affymetrix.
Nonconforming instruments will be serviced at Buyer’s facility or, at Affymetrix’ option, Affymetrix’ facility. 

  
 15 

	 	•	 	 For probe arrays or reagents reasonably determined by Affymetrix to be defective, independent of user error,
shall be replaced by Affymetrix on a 1:1, like-kind basis at no cost to Buyer or at Affymetrix’ discretion, as a credit for future purchases, provided that such defective probe arrays or reagents were used by Buyer prior to their expiration
date, or if there is no expiration date, the Products were used within six (6) months of receipt. The defect must be reported within thirty (30) days of discovery with appropriate detail to Affymetrix’ Technical Support team. If the
cause of the failure was due to an Affymetrix instrument malfunction, a replacement will be granted only during the instrument warranty period or if the instrument is under an instrument service contract, pursuant to the terms and conditions then in
effect. Third party reagents or consumables not purchased from or provided by Affymetrix are not covered under Affymetrix warranty. 

  

	 	•	 	 For Affymetrix Methods for Automated Target Preparation for GeneTitan®, subject to the conditions and limitations of liability stated herein, Affymetrix warrants, for one (1) year from the date of installation (“Warranty Period”) of the GeneTitan®, for the Buyer’s benefit that the Affymetrix methods for automated target preparation for the GeneTitan® family of instruments (the
“Method”) shall operate substantially in accordance with the accompanying documentation provided that; 

(i) the Method is installed by a qualified Affymetrix representative, (ii) the automated target preparation instrument is
installed by a qualified engineer and maintained under a valid service contract or warranty with the third party vendor, (iii) the Method is operated in accordance with the supplied technical instruction from Affymetrix, (iv) that the
associated storage media on which the Method resides is free from defects in material and workmanship. The foregoing warranty shall not apply to (i) Methods that are modified; (ii) Methods that are not the then-current version;
(iii) problems caused by Buyer’s negligence or error, a hardware malfunction or other causes beyond the control of Affymetrix; or (iv) Methods installed in an operating environment or in a hardware environment not strictly complying
with the Affymetrix specifications required for the Method set forth in the documentation. The warranty stated herein for the Methods do not cover damage to the automated target preparation instrument nor associated consumables and reagents not
supplied by Affymetrix. 
  

	 	•	 	 Technical Assistance: Affymetrix, may, but is not obligated to, furnish technical assistance and information
with respect to the Products. Any suggestions by Affymetrix regarding use, selection, application or suitability of the Products shall not be construed as a warranty. 

Except as provided above, any warranty provided herein does not apply to any consumables, including third party reagents, or to any defect
caused by Buyer’s failure to provide a suitable storage, use, or operating environment, use of non-recommended reagents, spills, or the use of the Products for a purpose or in a manner other than that for
which they were designed, modifications or repairs done by Buyer, or any other abuse, misuse, or neglect of the Products. Affymetrix is not responsible for any costs or expenses incurred by the Buyer due to downtime. Affymetrix may at any time stop
providing and supporting the Products (“End of Life”) and will use commercially reasonable efforts to communicate such End of Life events in advance. This warranty applies only to Buyer, and not third parties. Furthermore, this Warranty
stated herein shall not apply to product performance failures that are caused by users of the Affymetrix Products who were not trained on and qualified to use the Affymetrix Products and assays by an Affymetrix field service engineer, Affymetrix
application specialist, or an authorized Affymetrix seller. The foregoing is not intended to limit any warranty extended to Buyer by a third party original equipment manufacturer of a Product or component thereof, provided that any remedy received
by Buyer under any such warranty shall relieve Affymetrix of its obligations with respect to the subject of such remedy. TO THE EXTENT PERMITTED BY APPLICABLE LAW, AFFYMETRIX AND ITS SUPPLIERS DISCLAIM ALL OTHER REPRESENTATIONS AND WARRANTIES,
EXPRESS OR IMPLIED, WITH RESPECT TO PRODUCTS AND SERVICES, INCLUDING BUT NOT LIMITED TO, ANY IMPLIED WARRANTIES OF MERCHANTABILITY, SATISFACTORY QUALITY, NON-INFRINGEMENT OR FITNESS FOR A PARTICULAR PURPOSE.

 7. Pre-release Products (Not Applicable to Products Marketed for IVD Use). If any Product is a
beta, technology access, early access, or other pre-commercial release version (“Pre-release Product”), then this Section applies. To the extent that any
provision in this Section is in conflict with any other term or condition in these Terms and Conditions, this Section shall supersede such other term(s) and condition(s) with respect to the Pre-release
Product, but only to the extent necessary to resolve the conflict. Buyer acknowledges that the Pre-release Product is a pre-release version, does not represent final
product from Affymetrix, and may contain defects, bugs, errors and other problems that could cause system or other failures, sample loss and data loss. CONSEQUENTLY, THE PRE-RELEASE PRODUCT IS PROVIDED TO YOU
“AS IS” AND AFFYMETRIX DISCLAIMS ALL WARRANTIES (INCLUDING THE LIMITED WARRANTY SET FORTH ABOVE) AND ALL LIABILITY OBLIGATIONS TO BUYER OF ANY KIND. Buyer acknowledges that Affymetrix has not promised or guaranteed to Buyer that Pre-release Product will be announced or made available to anyone in the future, that Affymetrix has no express or implied obligation to Buyer to announce or introduce the
Pre-release Product and that Affymetrix may elect not to introduce a product similar to or compatible with the Pre-release Product. Accordingly, Buyer acknowledges that
any research or development that Buyer performs using the Pre-release Product or any product associated with the Pre-release Product is done entirely at Buyer’s own
risk. 
 8. Limited License. Subject to these Terms and Conditions, and to the terms and conditions of any license provided by Affymetrix
that is specific to a particular Product (which shall govern with respect to such Product in the event of conflict with these Terms and Conditions), Affymetrix hereby grants to Buyer a non-exclusive, non-transferable, non-sublicensable license to use the Product(s) provided to Buyer by Affymetrix only in accordance with the manuals and written instructions provided by
Affymetrix. Buyer understands and agrees that except as expressly set forth in these Terms and Conditions (or in the Affymetrix-provided license specific to a particular Product), no right or license to any patent or other intellectual property
owned or licensable by 

  
 16 

 
Affymetrix is conveyed or implied by these Terms and Conditions or any Product. In particular, no right or license is conveyed or implied to use any Product provided hereunder in combination with
a product not provided, licensed or specifically recommended by Affymetrix for such use. 
 9. Product Uses. Products of Affymetrix which
are or may be drugs, food additives or diagnostic reagents, as described in the federal food, drug and cosmetic act, are for investigational use only in laboratory research animals or testing in vitro, and are not for drug, new drug, veterinary
drug, food, food additive or human use. Unless otherwise indicated, all products are distributed and sold for chemical purposes only, not for drug use or for application to or ingestion by humans or for commercial horticulture use, for pesticide
use, for application to or ingestion by animals or for veterinary drug use. All products sold by Affymetrix to Buyer shall be used by qualified professionals only. The burden for safe use and handling of all products sold by Affymetrix to Buyer is
entirely the responsibility of Buyer and anyone who purchases the goods from Buyer and uses them. Absence of hazardous warnings does not imply non-toxicity. 

10. Products Marketed for Research Use Only. 
  

	 	(a)	 Products marketed by Affymetrix for research use only do not have the approval or clearance of the U.S. Food
and Drug Administration (“FDA”) or other regulatory approval, clearance or registration for in vitro diagnostic (“IVD”) use. No license is conveyed or implied for Buyer to use, and Buyer agrees not to use, such Products in any
manner requiring FDA or other regulatory approval, clearance or registration relating to IVD use. 

  

	 	(b)	 Affymetrix’ goods that are intended for research purposes may not be on the Toxic Substances Control
Act (“TSCA”) inventory. Buyer assumes responsibility to ensure that the goods purchased from Affymetrix are approved under TSCA, if applicable. Consistent with Buyer’s agreement to comply with all TSCA and Research and Development
substance exemption (the “R&D exemption”) requirements applicable to the purchase, Buyer agrees and warrants that Buyer will comply with all the requirements necessary to maintain the R&D exemption, including using the R&D
substance under the supervision of a technically qualified individual, maintaining all necessary labeling, and providing all necessary notifications. Buyer also agrees and warrants that Buyer will use or sell (if so authorized) the R&D substance
exclusively for R&D purposes or specified exempt commercial purposes. Buyer specifically agrees and warrants that Buyer will not sell or distribute the R&D substance to consumers. 

11. Products Marketed for In Vitro Diagnostic Use. Products marketed by Affymetrix for IVD use have been cleared by the FDA, and CE marked in
the European Union, for IVD use. No license is conveyed or implied for Buyer to use, and Buyer agrees not to use, such Products in any manner requiring other regulatory approval, clearance or registration relating to IVD use. The Affymetrix GeneChip® Array Instrumentation System for IVD use requires calibration and maintenance twice a year by authorized Affymetrix personnel to ensure system performance. Failure to maintain the system as
recommended may result in the failure of the system to perform in accordance with specifications published by Affymetrix. 
 12. Use
Restrictions. Buyer is not licensed to, and agrees not to: (a) resell any Affymetrix-supplied probe array or reagent, unless otherwise authorized by Affymetrix in writing (b) transfer, or distribute any Affymetrix-supplied probe array or
reagent, directly or indirectly, to any third party for any purpose or use, except as otherwise approved by Affymetrix in writing; (c) use or allow anyone to use any Affymetrix-supplied probe array or reagent more than once, or dilute any
Affymetrix-supplied reagent; or (d) provide a fee-for-service or other non-collaborative sample processing service to third
parties using an Affymetrix-supplied probe array or reagent (e.g., wherein the service provider offers standardized services for standardized fees to multiple third parties, the customer does not contribute scientifically to the services performed,
and all rights to the results and discoveries derived therefrom are transferred to the customer). 
 13. Product Improvements. Except to the
extent prohibited by applicable law, Buyer hereby grants to Affymetrix a non-exclusive, worldwide, fully paid-up, royalty-free license to all Product Improvements
provided that if the Product Improvements are incorporating Buyer’s proprietary technology or intellectual property, Buyer shall not be required to grant Affymetrix a license to such proprietary technology or intellectual property. Buyer need
not disclose any Product Improvements to Affymetrix except as may be reasonably required to comply with the foregoing license. For purposes of this Section, a “Product Improvement” shall mean any invention conceived or reduced to practice
using a Product that relates to(a) design, manufacturing, layout or packaging of nucleic acid probes or probe arrays; (b) manual or automated assay techniques that may be used in connection with probe arrays or similar products (including
techniques related to nucleic acid extraction, amplification, labeling, dilution and other processes); or (c) software analysis techniques relating to the extraction or storage of data generated using probe arrays. “Product
Improvements” shall not include data generated using Products or discoveries derived therefrom (except as expressly set forth in (a) - (c) above). 

14. Target Sequence Confidentiality for Custom Products. If Buyer discloses to Affymetrix a confidential set of nucleic acid or peptide target
sequences (“Target Sequences”) for which Buyer desires Affymetrix to design and manufacture custom probe arrays or custom protein assay or custom nucleic acid assay pursuant to these Terms and Conditions, upon Buyer’s written request,
Affymetrix agrees to not disclose or use such confidential information disclosed to it by Buyer for any purpose other than designing and manufacturing such Products, supplying them to Buyer and/or other parties designated by Buyer, otherwise
performing its obligations to Buyer (and any obligations Affymetrix may have to such other parties), and for other purposes authorized by Buyer. The provisions of this Section shall not apply to any information which (a) is known or used by
Affymetrix prior to Buyer’s disclosure to Affymetrix; (b) is disclosed to Affymetrix by a third party under no obligation of confidentiality to Buyer; (c) is or becomes published or generally known to the public through no fault of
Affymetrix; or (d) is independently developed without reference to such confidential information disclosed to Affymetrix by Buyer. Notwithstanding the foregoing, Affymetrix shall be permitted to disclose such information in order

  
 17 

 
to comply with applicable laws, a court order, or governmental regulations, provided that Affymetrix has provided Buyer with prior notice of such disclosure, to the extent reasonably practicable.
Affymetrix’s obligations under this Section shall terminate three (3) years following the date of disclosure. 
 15. Target
Sequence Responsibility. Buyer shall be fully responsible for the Target Sequences, including the obtaining of all required consents, and Buyer agrees to indemnify Affymetrix and its employees, officers, directors, representatives, contractors,
suppliers and any affiliate of the foregoing (the “Affymetrix Group”) and hold each of them harmless from and against any losses, liabilities, demands, damages, costs and expenses, including without limitation reasonable legal fees and
expenses, arising from or relating to the Target Sequences or their use. Buyer agrees to fully cooperate with the Affymetrix Group and its counsel in its defense and preparation for any such action or proceeding. 

16. Liability Limitation. EXCEPT TO THE EXTENT CAUSED BY AFFYMETRIX’S GROSS NEGLIGENCE OR WILLFUL MISCONDUCT, OR REQUIRED BY APPLICABLE
LAW, AFFYMETRIX SHALL HAVE NO LIABILITY FOR ANY LOSS OF USE OR PROFITS, PROCUREMENT OF SUBSTITUTE GOODS OR ANY INDIRECT, CONSEQUENTIAL, INCIDENTAL, OR SPECIAL DAMAGES OF ANY KIND, HOWEVER CAUSED AND REGARDLESS OF FORM OF ACTION WHETHER IN CONTRACT,
TORT (INCLUDING NEGLIGENCE), STRICT PRODUCT LIABILITY OR OTHERWISE, EVEN IF AFFYMETRIX HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES; AS TO ANY AFFYMETRIX LIABILITY NOT LEGALLY SUBJECT TO THE FOREGOING, AFFYMETRIX’S LIABILITY SHALL NOT
EXCEED THE AMOUNT PAID BY BUYER TO AFFYMETRIX DURING THE TERM OF THE AGREEMENT. BUYER UNDERSTANDS THAT THE RISKS OF LOSS HEREUNDER ARE REFLECTED IN THE PRICE OF THE PRODUCTS AND THAT THESE TERMS WOULD HAVE BEEN DIFFERENT IF THERE HAD BEEN A
DIFFERENT ALLOCATION OF RISK. 
 17. Export Controls. Buyer acknowledges that the Products and related materials may be subject to export
controls under the U.S. Export Administration Regulations and related U.S. laws. Buyer will (a) comply strictly with all legal requirements established under these controls, (b) cooperate fully with Affymetrix in any official or unofficial
audit or inspection that relates to these controls and (c) not export, re-export, divert, transfer or disclose, directly or indirectly, any Product or related technical documents or materials or any
direct product thereof to any country (or to any national or resident thereof which the U.S. Government determines from time to time is a country (or end-user) to which such export, re-export, diversion. transfer or disclosure is restricted, without obtaining the prior written authorization of Affymetrix and the applicable U.S. Government agency. 

18. Unforeseen Events. Affymetrix shall not be liable for delay or failure in performance of any obligations hereunder if performance is
rendered impracticable by the occurrence of any condition beyond the reasonable control of Affymetrix. In the event of any such delay or failure in performance, Affymetrix shall have such additional time within which to perform its obligations
hereunder as may reasonably be necessary under the circumstances. 
 19. Miscellaneous. These Terms and Conditions constitute the entire
agreement between Buyer and Affymetrix with respect to the subject matter hereof and is the final, complete, and exclusive statement of the terms of the agreement, superseding all prior written and oral agreements, understandings and undertakings
with respect to the subject matter hereof. The waiver of any provision or any breach thereof shall not affect any other provision of these Terms and Conditions. The U.N. Convention on Contracts for the International Sale of Goods shall not apply to
these Terms and Conditions. In the event that any provision of this Agreement or portion thereof is found to be illegal or unenforceable, the Agreement shall be construed without the unenforceable provision or portion thereof. 

20. Governing Law. 
 (a) For
Deliveries Outside Europe: To the extent permitted by applicable law, these Terms and Conditions shall be governed by and construed according to the laws of California, without regard to conflict of law provisions. 

(a) For Deliveries Within Europe: To the extent permitted by applicable law, these Terms and Conditions shall be governed by and construed
according to the laws of England, without regard to conflict of law provisions. 

  
 18 

 SCHEDULE C 

REGULATORY TERMS AND CONDITIONS 

“Regulatory Approval” means all approvals, registrations, certifications or market clearances required by
Regulatory Authorities. 
 “Regulatory    Authorities” means all governmental
agencies regulating the development, manufacture or use of Diagnostic Products or Diagnostic Services in any country or groups of countries. 

1. Regulatory Approvals. 

Partner shall, before its marketing, selling or distributing Diagnostic Products or Diagnostic Services for diagnostic
purposes, obtain Regulatory Approval for Partner’s Diagnostic Products. Affymetrix shall assist Partner in obtaining such Regulatory Approval, including without limitation, supply Partner with existing information regarding the Arrays or their
manufacture or use, that is necessary or useful for Partner’s regulatory filings on reasonable terms and conditions. Partner shall have the right to use and distribute Arrays for the purpose of investigational studies to determine the
performance characteristics of the Array prior to and, if necessary, after the Regulatory Approval of the Diagnostic Product incorporating such Arrays. Partner shall comply with regulatory requirements for investigational use in any territory in
which such Arrays are used. Partner is responsible for all design control activities relating to Partner’s use of the Arrays. 

Affymetrix will promptly provide existing applicable information to fulfill a Regulatory Authority’s inquiries and/or
requirements relating to a change in Affymetrix products or labeling. 
 Affymetrix will promptly notify Partner if it has
received written communication from any Regulatory Authority stipulating or threatening the stipulation of the cessation of the production or sale of the Arrays. 

Affymetrix will provide reasonable regulatory support to Partner in connection with or in support of US Class I or
Class II or CE Mark assay submission to a Regulatory Authority for Regulatory Clearance or Approval. Affymetrix will supply a right of reference letter for Partner to include in its assay submission so that FDA may access information within the
510(k) file for the [***]. As the [***] is currently self-certified under the IVDD directive, no cross reference to a Regulatory Authority is required for CE marking of Partner’s assay. Partner represents and warrants that the information
supplied by Partner to Affymetrix in connection with or in support of any submission to a Regulatory Authority for Regulatory Approval shall be accurate and complete and shall have been obtained in compliance with all applicable laws and
regulations, and Partner hereby gives Affymetrix permission to use and cross-reference such information as is required in connection with any regulatory filing relating to products for use with Diagnostic Products or Diagnostic Services. 

Partner covenants that all Diagnostic Products and Diagnostic Services provided by Partner in connection with this Agreement
(i) shall be designed, offered for sale or distribution and provided in a good and workmanlike manner, (ii) shall be designed, offered for sale or distribution and provided in compliance with this Agreement, and (iii) shall comply
with all applicable statutes, laws, ordinances and regulations then applicable to the design, performance and supply of such Diagnostic Products or Diagnostic Services (as the case may be), including, without limitation, those enforced or prescribed
(A) 

  

[***]=CONFIDENTIAL TREATMENT REQUESTED 

 
by the United States Food and Drug Administration (including compliance with good manufacturing practices) if sold with the U.S., (B) by the International Standards Organization (ISO) (if Partner
claims or otherwise represents compliance with any ISO standard(s)) when applicable, and (C) by any other relevant local authorities. 

Partner shall indemnify and hold harmless Affymetrix and its Affiliates and their officers, directors, employees, agents and representatives
for any breach of the foregoing covenant. 
 2. Notice of Defects and Deviations. 

Each Party shall immediately notify the other in writing, in no event more than three (3) days from date of discovery,
should it become aware, through Partner complaint or otherwise, of any defect or condition which may render any Instrument, Array or related reagent sold to a diagnostic end user in violation of FDA and/or any other applicable laws, rules or
regulations, or which may in any way deviate from the quality, specifications or warranties for any Instrument, Array or related reagent. 

3. Recalls. 

The Parties agree to cooperate with each other to enable them to satisfy their obligations as licensed
manufacturers/distributors of Instruments, Arrays or related reagents sold to diagnostic end users with respect to recalls, advisory notices, or field corrective actions relating to such Instruments, Arrays or reagents. 

4. Medical Device Reporting (MDR)/Reportable Incident. 

In the event that a Party becomes aware of information, from any source, that reasonably suggests that an Instrument, Array or
reagent manufactured by Affymetrix sold to a diagnostic end user may have caused or contributed to a death or serious injury or has malfunctioned and if the malfunction were to recur, it would likely cause or contribute to a death or serious injury,
then such Party shall (i) notify the other via phone call to such Party’s authorized representative for regulatory affairs as soon as possible, and in any case within 72 hours for serious injury or death, and (ii) immediately notify
the other in writing of the facts surrounding such situation to the best knowledge of the Party providing the notice. The Parties shall cooperate and work together to obtain details to make the MDR decision to meet reporting requirements by any
applicable governmental regulation, law, or other requirement. Both Parties shall use commercially reasonable efforts to investigate fully the root cause of any such incident or malfunction. 

5. Failure to Comply with Legal or Regulatory Regime. 

In the event that a Party to this Agreement is advised in writing by the USFDA, ISO registrar or notified body, or by an
analogous national governmental regulatory authority of the United States, the European Union or a European country or any other country in the Territory, that such Party’s activities in connection with Instruments, Arrays, or related reagents
(or products that incorporate any of the foregoing) do not comply with applicable laws and/or other regulatory requirement (excluding laws and regulations relating solely to the protection of intellectual property), the other Party will be promptly
notified in writing. The Parties agree to cooperate in good faith to resolve the regulatory authority’s concerns. Neither Party shall be required to continue activities that it has reasonable cause to believe may place it in violation of one or
more regulatory requirements. In such case, the affected Party may provide written notice to the other Party detailing the affected Party’s concerns. Unless a Party submits an acceptable written plan within thirty days of such noncompliance
notice by the Regulatory Authority that will allow such Party to achieve compliance within the following 90 days, the other Party shall no longer be required to perform under this Agreement. Upon eventual compliance by the Party with the Regulatory
Authority, the other Party shall recommence performance under this Agreement. 

 6. Review of Partner’s Use of Products. 

Affymetrix shall have a limited right to review Partner’s use of the Affymetrix Products supplied under this Agreement to
determine whether the use of such products in Partner’s Diagnostic Products and Diagnostic Services is consistent with the terms of this Agreement. Such review, if conducted, may include a review of Partner’s past ordering patterns and a
review of Partner’s Diagnostic Products and Diagnostic Services development plans and marketing information for the following two quarters. The review of Partner’s use of products and services shall be allowed [***] per year at a mutually
convenient date on the premises and during the regular business hours of Partner at the written request of Affymetrix [***] prior to the proposed review date and at the expense of Affymetrix. All information gathered by Affymetrix shall be
considered Confidential Information of Partner and shall not be removed from Partner’s premises except with the written permission of Partner and after having been stamped as Confidential Information and dated. Such review shall be allowed for
compliance verification purposes only. 
 A reciprocal right is granted to Partner to review not more than [***] a year,
with [***] prior written notice, product design and manufacturing by Affymetrix of Affymetrix Products that are supplied to Partner under this Agreement and in conformity with applicable quality control standards, under the same conditions as
provided above. 
 7. Compliance with Law. 

Affymetrix shall comply with all laws, regulations and requirements applicable to Affymetrix as a supplier of the Affymetrix
Products, including QA Standards and any other regulations promulgated from time to time by the FDA and any other governmental authority that has jurisdiction over Affymetrix’s manufacture, supply, testing, packaging, processing, storage, or
distribution of the Affymetrix Products or over any Affymetrix facility. Affymetrix represents, warrants and covenants that it has, and will continue to have and maintain throughout the term of the Agreement at Affymetrix’s expense all permits,
approvals and authorizations, including, without limitation, such approvals as may be required under applicable law, to manufacture and sell Affymetrix Products in the Territory. 

8. Records: Samples. 

Affymetrix shall keep, or cause to be kept, complete, accurate and authentic accounts, notes, data and records pertaining to
the manufacture, processing, testing, labeling, storage, and distribution of Affymetrix Products sold to Partner, including without limitation master production and control records, and shall retain, or cause to be retained, samples of such
Affymetrix Products, in each case accordance with applicable laws and regulations. Affymetrix shall retain, or cause to be retained, such records for a period of [***] years following the date of manufacture, and such retained samples for a period
of [***] after the product expiration date. Upon request, Affymetrix shall make available for Partner’s review such records and retained samples. 

  

[***]=CONFIDENTIAL TREATMENT REQUESTED 

 SCHEDULE D 

INSURANCE REQUIREMENTS 
  

	1.	 Commercial General Liability Insurance in an amount not less than [***] per occurrence and not less than
[***] annual aggregate, bodily injury/property damage combined. 

  

	2.	 Errors and Omissions Insurance in an amount not less than [***] per occurrence and not less than [***]
annual aggregate, bodily injury/property damage combined. 

  

[***]=CONFIDENTIAL TREATMENT REQUESTED 

 SCHEDULE E 

[***] 

  

[***]=CONFIDENTIAL TREATMENT REQUESTED 

 SCHEDULE F 

PAYMENT PLAN 
 [***] 

  

[***]=CONFIDENTIAL TREATMENT REQUESTED

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}]]